Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention


  Free Subscription

Articles published in Leuk Lymphoma

Retrieve available abstracts of 411 articles:
HTML format

Single Articles

    June 2022
  1. XU GF, Liu LM, Wang M, Zhang ZB, et al
    Treatments of Ph-like acute lymphoblastic leukemia: a real-world retrospective analysis from a single large center in China.
    Leuk Lymphoma. 2022 Jun 24:1-11. doi: 10.1080/10428194.2022.2090550.
    PubMed     Abstract available

  2. RAA DGT, van der Straten L, van Gelder M, Kersting S, et al
    Diagnosis, treatment and supportive management of chronic lymphocytic leukemia: recommendations of the Dutch HOVON CLL working group.
    Leuk Lymphoma. 2022 Jun 23:1-14. doi: 10.1080/10428194.2022.2084731.
    PubMed     Abstract available

  3. DHAKAL P, Joshi U, Lyden E, Pyakuryal A, et al
    Association of insurance types and outcomes in acute promyelocytic leukemia.
    Leuk Lymphoma. 2022 Jun 23:1-9. doi: 10.1080/10428194.2022.2090554.
    PubMed     Abstract available

  4. ZONG L, Xie J, Kong J, Bao X, et al
    Lineage switch from acute myeloid leukemia to acute lymphoblastic leukemia.
    Leuk Lymphoma. 2022 Jun 23:1-3. doi: 10.1080/10428194.2022.2064984.

  5. SERPENTI F, Sciume M, Galassi G, Saporiti G, et al
    Off-label venetoclax in combination with hypomethylating agents for post-allogeneic stem cell transplant acute myeloid leukemia relapse.
    Leuk Lymphoma. 2022 Jun 22:1-4. doi: 10.1080/10428194.2022.2090553.

  6. NGO D, Otoukesh S, Stein AS, Forman S, et al
    The safety of concurrent intrathecal chemotherapy during blinatumomab in adults with acute lymphoblastic leukemia.
    Leuk Lymphoma. 2022 Jun 21:1-3. doi: 10.1080/10428194.2022.2090555.

  7. TEDJASEPUTRA A, Kuzich JA, Thiagarajah N, Teh TC, et al
    Hyperleukocytosis associated with delayed presentation among patients with acute leukemia during the COVID-19 pandemic.
    Leuk Lymphoma. 2022 Jun 21:1-4. doi: 10.1080/10428194.2022.2087065.

  8. KOHN M, Alsuliman T, Lamure S, Cheminant M, et al
    Characteristics of SARS-CoV-2 infection in lymphoma/chronic lymphocytic leukemia patients during the Omicron outbreak.
    Leuk Lymphoma. 2022 Jun 18:1-5. doi: 10.1080/10428194.2022.2086249.

  9. MOLICA S, Allsup DJ, Polliack A
    Adherence to ibrutinib remains an unmet clinical need in chronic lymphocytic leukemia.
    Leuk Lymphoma. 2022 Jun 15:1-3. doi: 10.1080/10428194.2022.2087072.

  10. YU G, Lu W, Chen X, Li Y, et al
    Single-cell RNA sequencing to explore composition of peripheral blood NK cells in patients with chronic myeloid leukemia in treatment-free remission.
    Leuk Lymphoma. 2022 Jun 11:1-12. doi: 10.1080/10428194.2022.2086243.
    PubMed     Abstract available

  11. LYU X, Li T, Zhu D, Cheng Y, et al
    Whole-genome sequencing as an alternative to analyze copy number abnormalities in acute myeloid leukemia and myelodysplastic syndrome.
    Leuk Lymphoma. 2022 Jun 11:1-10. doi: 10.1080/10428194.2022.2080821.
    PubMed     Abstract available

  12. SABURI M, Sakata M, Takata H, Miyazaki Y, et al
    Poor clinical outcome of elderly patients with primary plasma cell leukemia treated with novel agents: real-world experience.
    Leuk Lymphoma. 2022 Jun 10:1-5. doi: 10.1080/10428194.2022.2086250.

  13. XU J, Hao Z, Chen X, Hong M, et al
    The characteristics and clinical prognosis analysis of ASXL1 mutations in Chinese adult patients with primary cytogenetically normal acute myeloid leukemia by next-generation sequencing.
    Leuk Lymphoma. 2022 Jun 2:1-9. doi: 10.1080/10428194.2022.2081323.
    PubMed     Abstract available

  14. GADAUD N, Leroy H, Berard E, Tavitian S, et al
    Azacitidine, intensive chemotherapy or best supportive care in relapsed or refractory acute myeloid leukemia, a DATAML registry study.
    Leuk Lymphoma. 2022;63:1398-1406.
    PubMed     Abstract available

  15. MATUTES E, Polliack A
    Is ibrutinib the gold standard for therapy - naive elderly patients with CLL?
    Leuk Lymphoma. 2022;63:1265-1266.

  16. TAHIR F, Sy J, Reddel S, Trotman J, et al
    Progressive multifocal leukoencephalopathy post ibrutinib therapy in relapsed chronic lymphocytic leukaemia.
    Leuk Lymphoma. 2022;63:1464-1468.
    PubMed     Abstract available

  17. SHARPLIN KM, Marks DI
    The treatment landscape for Relapsed Refractory B Acute Lymphoblastic Leukaemia (ALL).
    Leuk Lymphoma. 2022;63:1292-1301.
    PubMed     Abstract available

  18. BALL S, Komrokji RS, Sallman DA
    Prognostic scoring systems and risk stratification in myelodysplastic syndrome: focus on integration of molecular profile.
    Leuk Lymphoma. 2022;63:1281-1291.
    PubMed     Abstract available

    May 2022
  19. MAENG CV, Christiansen CF, Liu KD, Kamper P, et al
    Factors associated with risk and prognosis of intensive care unit admission in patients with acute leukemia: a Danish nationwide cohort study.
    Leuk Lymphoma. 2022 May 18:1-11. doi: 10.1080/10428194.2022.2074984.
    PubMed     Abstract available

  20. MACHHERNDL-SPANDL S, Vockenhuber T, Binder M, Weltermann A, et al
    Efficacy and safety of voriconazole as invasive fungal infection prophylaxis in patients with acute myeloid leukemia.
    Leuk Lymphoma. 2022 May 13:1-6. doi: 10.1080/10428194.2022.2068006.
    PubMed     Abstract available

  21. LI Z, Peng L, Li Y, Zhang J, et al
    Lower tumor burden is associated with better cognitive function in patients with chronic phase chronic myeloid leukemia.
    Leuk Lymphoma. 2022 May 11:1-12. doi: 10.1080/10428194.2022.2070912.
    PubMed     Abstract available

  22. ASOUBAR S, Esfahani A, Vahedi A, Mohammadi SM, et al
    Responsible enzymes for metabolizing vitamin D in patients with acute leukemia and the relationship with treatment outcomes: a case-control study.
    Leuk Lymphoma. 2022 May 4:1-7. doi: 10.1080/10428194.2022.2056174.
    PubMed     Abstract available

  23. SZCZEPANEK E, Chukwu O, Kaminska M, Wysoglad H, et al
    Long-term outcomes of patients with Chronic Myeloid Leukemia who commenced treatment with imatinib: a 20-year single-centre experience.
    Leuk Lymphoma. 2022 May 2:1-11. doi: 10.1080/10428194.2022.2068000.
    PubMed     Abstract available

  24. PREBET T, Goldberg AD, Jurcic JG, Khaled S, et al
    A phase 1b study of atezolizumab in combination with guadecitabine for the treatment of acute myeloid leukemia.
    Leuk Lymphoma. 2022 May 1:1-9. doi: 10.1080/10428194.2022.2057484.
    PubMed     Abstract available

  25. QIN T, Cheng Y, Wang X
    RNA-binding proteins as drivers of AML and novel therapeutic targets.
    Leuk Lymphoma. 2022;63:1045-1057.
    PubMed     Abstract available

  26. SAUMELL S, Fernandez-Serrano M, Mesa A, Lopez-Cadenas F, et al
    Prognostic impact of micromegakaryocytes in primary myelodysplastic syndromes.
    Leuk Lymphoma. 2022;63:1227-1235.
    PubMed     Abstract available

  27. LI J, Liao D, Wang F, Wang Z, et al
    RIPK1 inhibition enhances the therapeutic efficacy of chidamide in FLT3-ITD positive AML, both in vitro and in vivo.
    Leuk Lymphoma. 2022;63:1167-1179.
    PubMed     Abstract available

    April 2022
  28. QI D, Wang J, Zhao Y, Yang Y, et al
    JMJD1C-regulated lipid synthesis contributes to the maintenance of MLL-rearranged acute myeloid leukemia.
    Leuk Lymphoma. 2022 Apr 25:1-12. doi: 10.1080/10428194.2022.2068004.
    PubMed     Abstract available

  29. LI Q, Liang C, Xu X, Zhang C, et al
    CLEC12A plays an important role in immunomodulatory function and prognostic significance of patients with acute myeloid leukemia.
    Leuk Lymphoma. 2022 Apr 23:1-13. doi: 10.1080/10428194.2022.2064986.
    PubMed     Abstract available

  30. PHAM TM, Quy PN, Amin K, Walker E, et al
    Average lifespan shortened due to Hodgkin lymphoma, non-Hodgkin lymphoma, multiple myeloma, and leukemia in Japan, 1990-2015.
    Leuk Lymphoma. 2022 Apr 23:1-10. doi: 10.1080/10428194.2022.2064990.
    PubMed     Abstract available

  31. PETROV D, Timilshina N, Papadopoulos E, Alibhai SMH, et al
    Performance of the frailty index in predicting complete remission, intensive care unit admission, and overall mortality in older and younger patients with acute myeloid leukemia receiving intensive chemotherapy.
    Leuk Lymphoma. 2022 Apr 22:1-8. doi: 10.1080/10428194.2022.2064993.
    PubMed     Abstract available

  32. MEMOLI M, Genthon A, Favale F, Lapusan S, et al
    Prognostic impact of early minimal residual disease combined with complete molecular evaluation in acute myeloid leukemia with mutated NPM1: a single center study.
    Leuk Lymphoma. 2022 Apr 22:1-9. doi: 10.1080/10428194.2022.2064987.
    PubMed     Abstract available

  33. SHORT NJ, Borthakur G, Pemmaraju N, Dinardo CD, et al
    A multi-arm phase Ib/II study designed for rapid, parallel evaluation of novel immunotherapy combinations in relapsed/refractory acute myeloid leukemia.
    Leuk Lymphoma. 2022 Apr 20:1-10. doi: 10.1080/10428194.2022.2062345.
    PubMed     Abstract available

  34. NAKASE K, Tanaka I, Tawara I, Shiku H, et al
    CD22 expression in acute myeloid leukemia: close correlation with interleukin-2 receptor alpha-chain (CD25) expression and poor prognosis.
    Leuk Lymphoma. 2022 Apr 20:1-3. doi: 10.1080/10428194.2022.2062346.

  35. XUE S, Huang W, Liu F, Zhang Y, et al
    Rapid response to avapritinib of acute myeloid leukemia with t(8;21) and KIT mutation relapse post allo-HSCT.
    Leuk Lymphoma. 2022 Apr 19:1-4. doi: 10.1080/10428194.2022.2064994.

  36. MIRANTI E, Ho DY, Enriquez K, Subramanian AK, et al
    Epidemiology of invasive fungal diseases in adults with newly diagnosed acute myeloid leukemia.
    Leuk Lymphoma. 2022 Apr 12:1-7. doi: 10.1080/10428194.2022.2060504.
    PubMed     Abstract available

  37. MANGAONKAR AA, Patnaik MM
    Role of the bone marrow immune microenvironment in chronic myelomonocytic leukemia pathogenesis: novel mechanisms and insights into clonal propagation.
    Leuk Lymphoma. 2022 Apr 4:1-9. doi: 10.1080/10428194.2022.2056175.
    PubMed     Abstract available

  38. MINDIOLA ROMERO AE, Johnston MA, Giffin JT, Khan WA, et al
    SNP-based chromosomal microarray characterization in a series of pure erythroid leukemia.
    Leuk Lymphoma. 2022 Apr 3:1-4. doi: 10.1080/10428194.2022.2057489.

  39. FERNANDEZ A, Perez-Martinez A, Escudero A, Mirones I, et al
    Infusion of haploidentical NKG2D-CAR-TCD45RA- cells in two pediatric patients with advanced relapsed and refractory acute leukemia was safe but achieved no clinical benefits.
    Leuk Lymphoma. 2022 Apr 3:1-5. doi: 10.1080/10428194.2022.2057490.

  40. HADDAD F, Kantarjian H, Issa GC, Jabbour E, et al
    Intracranial hypertension associated with BCR-ABL1 tyrosine kinase inhibitors in chronic myeloid leukemia.
    Leuk Lymphoma. 2022 Apr 1:1-4. doi: 10.1080/10428194.2022.2045599.

  41. MIYAMOTO T, Sanford D, Tomuleasa C, Hsiao HH, et al
    Real-world treatment patterns and clinical outcomes in patients with AML unfit for first-line intensive chemotherapy().
    Leuk Lymphoma. 2022;63:928-938.
    PubMed     Abstract available

    March 2022
  42. KIERDORF F, Zimmer P, Joisten N, Kiesl D, et al
    L-kynurenine as a prognostic marker for early mortality in patients with acute myeloid leukemia.
    Leuk Lymphoma. 2022 Mar 31:1-4. doi: 10.1080/10428194.2022.2053534.

  43. OCHS MA, Marini BL, Benitez LL, Stump SE, et al
    Multicenter comparison of first salvage chemotherapy versus novel therapy regimens in adult relapsed/refractory acute lymphoblastic leukemia.
    Leuk Lymphoma. 2022 Mar 28:1-10. doi: 10.1080/10428194.2022.2053530.
    PubMed     Abstract available

  44. PERKINS B, Showel M, Schoch L, Imus PH, et al
    CD34+ cell of origin for immunoglobulin heavy chain variable region unmutated, but not mutated, chronic lymphocytic leukemia.
    Leuk Lymphoma. 2022 Mar 27:1-7. doi: 10.1080/10428194.2022.2038375.
    PubMed     Abstract available

  45. DEODATO M, Frustaci AM, Sportoletti P, Laurenti L, et al
    How COVID-19 pandemic changed our attitude to venetoclax-based treatment in chronic lymphocytic leukemia.
    Leuk Lymphoma. 2022 Mar 27:1-4. doi: 10.1080/10428194.2022.2053532.

  46. LIPTON NJ, Lipton JH
    Making the case for the case report - informing physicians of intracranial hypertension as an adverse event in tyrosine kinase inhibitor treated chronic myeloid leukemia patients.
    Leuk Lymphoma. 2022 Mar 25:1-2. doi: 10.1080/10428194.2022.2056180.

  47. GHOSH S, Roth J, Babushok D, Lim M, et al
    Significance of RUNX1 mutation in BCR-ABL1 positive acute myeloid leukemia - a diagnostic dilemma in a young woman with persistent bleeding.
    Leuk Lymphoma. 2022 Mar 15:1-5. doi: 10.1080/10428194.2022.2047673.

  48. GRAVENO ME, Carulli A, Freyer CW, Mangan BL, et al
    Venetoclax in combination with hypomethylating agents or low dose cytarabine for relapsed and refractory acute myeloid leukemia.
    Leuk Lymphoma. 2022 Mar 8:1-6. doi: 10.1080/10428194.2022.2042688.
    PubMed     Abstract available

  49. TETTAMANTI S, Rotiroti MC, Giordano Attianese GMP, Arcangeli S, et al
    Lenalidomide enhances CD23.CAR T cell therapy in chronic lymphocytic leukemia.
    Leuk Lymphoma. 2022 Mar 8:1-14. doi: 10.1080/10428194.2022.2043299.
    PubMed     Abstract available

  50. XIE W, Raess PW, Dunlap J, Hoyos CM, et al
    Adult acute myeloid leukemia patients with NUP98 rearrangement have frequent cryptic translocations and unfavorable outcome.
    Leuk Lymphoma. 2022 Mar 8:1-10. doi: 10.1080/10428194.2022.2047672.
    PubMed     Abstract available

  51. COLLARD JP, McKenna MK, Noothi SK, Alhakeem SS, et al
    Role of the splenic microenvironment in chronic lymphocytic leukemia development in Emicro-TCL1 transgenic mice.
    Leuk Lymphoma. 2022 Mar 8:1-13. doi: 10.1080/10428194.2022.2045596.
    PubMed     Abstract available

  52. ESHIBONA N, Giwa A, Rossouw SC, Gamieldien J, et al
    Upregulation of FHL1, SPNS3, and MPZL2 predicts poor prognosis in pediatric acute myeloid leukemia patients with FLT3-ITD mutation.
    Leuk Lymphoma. 2022 Mar 6:1-10. doi: 10.1080/10428194.2022.2045594.
    PubMed     Abstract available

  53. COLLINS J 4TH, Stump SE, Heiling H, Muir M, et al
    Impact of adherence to ibrutinib on clinical outcomes in real-world patients with chronic lymphocytic leukemia.
    Leuk Lymphoma. 2022 Mar 6:1-8. doi: 10.1080/10428194.2022.2045597.
    PubMed     Abstract available

  54. GUPTA DG, Varma N, Kumar A, Naseem S, et al
    PHi-RACE: PGIMER in-house rapid & cost effective classifier for the detection of BCR-ABL1-like acute lymphoblastic leukaemia in Indian patients.
    Leuk Lymphoma. 2022;63:633-643.
    PubMed     Abstract available

  55. BENDIG S, Stengel A, Walter W, Meggendorfer M, et al
    Diagnostic challenge of identifying cases with recurrent t(8;14)(q24.21;q32.2) Involving BCL11B in acute leukemias of ambiguous lineage: an analysis of eight patients.
    Leuk Lymphoma. 2022;63:747-750.

    February 2022
  56. FU W, Huang A, Xu L, Peng Y, et al
    Cytogenetic abnormalities in NPM1-mutated acute myeloid leukemia.
    Leuk Lymphoma. 2022 Feb 28:1-8. doi: 10.1080/10428194.2022.2045600.
    PubMed     Abstract available

  57. SIDDIQI T, Coutre S, McKinney M, Barr PM, et al
    Characterization of low-grade arthralgia, myalgia, and musculoskeletal pain with ibrutinib therapy: pooled analysis of clinical trials in patients with chronic lymphocytic leukemia and mantle cell lymphoma.
    Leuk Lymphoma. 2022 Feb 28:1-9. doi: 10.1080/10428194.2022.2038372.
    PubMed     Abstract available

  58. MUKHERJEE A, Milton DR, Jabbour EJ, Gulbis AM, et al
    Clinical outcome of allogeneic stem cell transplantation in patients with B-cell lymphoid malignancies following treatment with targeted small molecule inhibitors.
    Leuk Lymphoma. 2022 Feb 27:1-9. doi: 10.1080/10428194.2022.2043302.
    PubMed     Abstract available

  59. VALDEZ BC, Yuan B, Murray D, Nieto Y, et al
    Enhanced cytotoxicity of bisantrene when combined with venetoclax, panobinostat, decitabine and olaparib in acute myeloid leukemia cells.
    Leuk Lymphoma. 2022 Feb 20:1-11. doi: 10.1080/10428194.2022.2042689.
    PubMed     Abstract available

  60. KAUMEYER B, Fidai S, Sukhanova M, Yap KL, et al
    MUC4 expression by immunohistochemistry is a specific marker for BCR-ABL1+ and BCR-ABL1-like B-lymphoblastic leukemia.
    Leuk Lymphoma. 2022 Feb 16:1-9. doi: 10.1080/10428194.2022.2025797.
    PubMed     Abstract available

  61. KOCHNEVA CAPITAL O, CYRILLICL, Kislova M, Zhelnova EI, Petrenko AA, et al
    COVID-19 in patients with chronic lymphocytic leukemia: a Moscow observational study.
    Leuk Lymphoma. 2022 Feb 13:1-10. doi: 10.1080/10428194.2022.2034157.
    PubMed     Abstract available

  62. AKHTAR OS, Groman A, Singh A, Ghione P, et al
    Frequency and timing of other primary cancers in patients with chronic lymphocytic leukemia (CLL): a 17-year longitudinal study.
    Leuk Lymphoma. 2022 Feb 13:1-10. doi: 10.1080/10428194.2021.2012662.
    PubMed     Abstract available

  63. FAZIO F, Cunsolo G, Mancini F, De Propris MS, et al
    Blast morphology in the diagnostic work-up of Ph-like acute lymphoblastic leukemia.
    Leuk Lymphoma. 2022 Feb 8:1-3. doi: 10.1080/10428194.2022.2032035.

  64. YUAN Y, Li J, Xue TL, Hu HR, et al
    Prognostic significance of NOTCH1/FBXW7 mutations in pediatric T cell acute lymphoblastic leukemia: a study of minimal residual disease risk-directed CCLG-ALL 2008 treatment protocol.
    Leuk Lymphoma. 2022 Feb 6:1-10. doi: 10.1080/10428194.2022.2032033.
    PubMed     Abstract available

  65. SHALLIS RM, Gore SD
    Agent Orange and dioxin-induced myeloid leukemia: a weaponized vehicle of leukemogenesis.
    Leuk Lymphoma. 2022 Feb 2:1-10. doi: 10.1080/10428194.2022.2034156.
    PubMed     Abstract available

  66. RAMALINGAM TR, Mohanraj S, Muthu A, Prabhakar V, et al
    Independent diagnostic utility of CD20, CD200, CD43 and CD45 in chronic lymphocytic leukaemia.
    Leuk Lymphoma. 2022;63:377-384.
    PubMed     Abstract available

    January 2022
  67. ROY T, An JB, Doucette K, Chappell AM, et al
    Venetoclax in upfront induction therapy for primary plasma cell leukemia with t(11;14) or BCL2 expression.
    Leuk Lymphoma. 2022 Jan 25:1-3. doi: 10.1080/10428194.2021.2010065.

  68. AMREIN P, Ballen K, Stevenson K, Brunner A, et al
    Ixazomib in addition to chemotherapy for the treatment of acute lymphoblastic leukemia in older adults.
    Leuk Lymphoma. 2022 Jan 25:1-8. doi: 10.1080/10428194.2021.2018582.
    PubMed     Abstract available

  69. CHAUDHARY S, Ganguly S, Singh A, Palanichamy JK, et al
    Mitochondrial biogenesis gene POLG correlates with outcome in pediatric acute myeloid leukemia.
    Leuk Lymphoma. 2022 Jan 25:1-4. doi: 10.1080/10428194.2021.2010063.

  70. MELEN CM, Merrien M, Wasik AM, Panagiotidis G, et al
    Clinical effects of a single dose of cannabinoids to patients with chronic lymphocytic leukemia.
    Leuk Lymphoma. 2022 Jan 17:1-11. doi: 10.1080/10428194.2021.2020776.
    PubMed     Abstract available

  71. BURGER JA, Robak T, Demirkan F, Bairey O, et al
    Up to 6.5 years (median 4 years) of follow-up of first-line ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma and high-risk genomic features: integrated analysis of two phase 3 studies.
    Leuk Lymphoma. 2022 Jan 11:1-12. doi: 10.1080/10428194.2021.2020779.
    PubMed     Abstract available

  72. SASAKI K, Kantarjian H, Jabbour E
    Prediction for sustained deep molecular response for treatment-free remission.
    Leuk Lymphoma. 2022;63:5-6.

  73. WILSON NR, Bover L, Konopleva M, Han L, et al
    CD303 (BDCA-2) - a potential novel target for therapy in hematologic malignancies.
    Leuk Lymphoma. 2022;63:19-30.
    PubMed     Abstract available

  74. HALPERN AB, Othus M, Howard NP, Hendrie PC, et al
    Comparative analysis of infectious complications with outpatient vs. inpatient care for adults with high-risk myeloid neoplasm receiving intensive induction chemotherapy.
    Leuk Lymphoma. 2022;63:142-151.
    PubMed     Abstract available

  75. EL HUSSEIN S, Hu S, Fang H, Garces S, et al
    Well-differentiated systemic mastocytosis with associated myeloid sarcoma and myelodysplastic syndrome: Diagnostic challenges of an underrecognized entity.
    Leuk Lymphoma. 2022;63:235-238.

    December 2021
  76. MESSORI A, Rivano M, Mengato D, Cancanelli L, et al
    A preliminary estimate of survival gain and cost-effectiveness of CAR-T in adult patients with acute lymphoblastic leukemia.
    Leuk Lymphoma. 2021 Dec 31:1-4. doi: 10.1080/10428194.2021.2022141.

  77. ROBOZ GJ, Yee K, Verma A, Borthakur G, et al
    Phase I trials of the lysine-specific demethylase 1 inhibitor, GSK2879552, as mono- and combination-therapy in relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndromes.
    Leuk Lymphoma. 2021 Dec 19:1-5. doi: 10.1080/10428194.2021.2012667.

  78. MCQUILTEN ZK, Busija L, Seymour JF, Stanworth S, et al
    Hemoglobin is a key determinant of quality of life before and during azacitidine-based therapy for myelodysplasia and low blast count acute myeloid leukemia.
    Leuk Lymphoma. 2021 Dec 17:1-8. doi: 10.1080/10428194.2021.2012664.
    PubMed     Abstract available

  79. HUNTINGTON SF, Ingham MP, Okonkwo L, Singh A, et al
    Treatment patterns, economic burden, and overall survival in US Medicare Advantage beneficiaries newly diagnosed with acute myeloid leukemia (AML) in 2015-2020.
    Leuk Lymphoma. 2021 Dec 16:1-11. doi: 10.1080/10428194.2021.2012666.
    PubMed     Abstract available

  80. KANAGAL-SHAMANNA R, Bao H, Kearney H, Smoley S, et al
    Molecular characterization of Novel ATM fusions in chronic lymphocytic leukemia and T-cell prolymphocytic leukemia.
    Leuk Lymphoma. 2021 Dec 13:1-11. doi: 10.1080/10428194.2021.2010061.
    PubMed     Abstract available

  81. CABRERA ME, Marinov N, Roa M, Castillo JJ, et al
    Epidemiology of chronic lymphocytic leukemia in Chilean and Amerindian population in Chile.
    Leuk Lymphoma. 2021 Dec 10:1-7. doi: 10.1080/10428194.2021.2012663.
    PubMed     Abstract available

  82. SALHOTRA A, Yang D, Mokhtari S, Hui S, et al
    Long-term follow-up of patients with poor-risk acute leukemia treated on a phase 2 trial undergoing intensified conditioning regimen prior to allogeneic hematopoietic cell transplantation.
    Leuk Lymphoma. 2021 Dec 9:1-7. doi: 10.1080/10428194.2021.2012661.
    PubMed     Abstract available

  83. SHEN X, Zhang L, Xing S, Zhang XW, et al
    Inhibition of pyrimidine biosynthesis by strobilurin derivatives induces differentiation of acute myeloid leukemia cells.
    Leuk Lymphoma. 2021 Dec 8:1-9. doi: 10.1080/10428194.2021.2008382.
    PubMed     Abstract available

  84. EGELI DB, Hanfstein B, Lauseker M, Pfirrmann M, et al
    SOCS-2 gene expression at diagnosis does not predict for outcome of chronic myeloid leukemia patients on imatinib treatment.
    Leuk Lymphoma. 2021 Dec 6:1-8. doi: 10.1080/10428194.2021.2010059.
    PubMed     Abstract available

  85. BANASZAK LG, Reinig E, Lasarev MR, Mattison RJ, et al
    Clinical utility and real-world application of molecular genetic sequencing in the management of patients with acute myeloid leukemia and myelodysplastic syndromes.
    Leuk Lymphoma. 2021 Dec 6:1-10. doi: 10.1080/10428194.2021.1999435.
    PubMed     Abstract available

  86. GAGEZ AL, Paul F, Alaterre E, Gouilleux-Gruart V, et al
    Angiogenic factors could help us to define patients obtaining complete response with undetectable minimal residual disease in untreated CLL patients treated by FCR: results from the CLL2010FMP, a FILO study.
    Leuk Lymphoma. 2021;62:3160-3169.
    PubMed     Abstract available

  87. BEWERSDORF JP, Stone RM, Tallman MS, Stahl M, et al
    Does the conventional cytogenetic risk profile still matter for prediction of venetoclax based treatment outcomes in AML?
    Leuk Lymphoma. 2021;62:3318-3319.

  88. BEWERSDORF JP, Derkach A, Gowda L, Menghrajani K, et al
    Venetoclax-based combinations in AML and high-risk MDS prior to and following allogeneic hematopoietic cell transplant.
    Leuk Lymphoma. 2021;62:3394-3401.
    PubMed     Abstract available

  89. SMALL SH, Altman JK, Platanias LC
    Interferon maintenance for prevention of relapse in favorable risk AML?
    Leuk Lymphoma. 2021;62:2818-2819.

  90. STABER PB, Jurczak W, Greil R, Vucinic V, et al
    Tafasitamab combined with idelalisib or venetoclax in patients with CLL previously treated with a BTK inhibitor.
    Leuk Lymphoma. 2021;62:3440-3451.
    PubMed     Abstract available

  91. LUKES J, Wolthers BO, Altaf Raja R, Uhrinova K, et al
    Pancreatitis-associated protein as an early marker of asparaginase-associated pancreatitis.
    Leuk Lymphoma. 2021;62:3506-3510.

  92. LU H, Li ZY, Ding M, Liang C, et al
    Trametinib enhances ATRA-induced differentiation in AML cells.
    Leuk Lymphoma. 2021;62:3361-3372.
    PubMed     Abstract available

  93. LOO S, Wei AH
    Post-transplant maintenance therapy for MDS and AML: a bridge too far or the beginning of a new era?
    Leuk Lymphoma. 2021;62:3073-3077.

  94. WAGNER-JOHNSTON ND, Sharman J, Furman RR, Salles G, et al
    Idelalisib immune-related toxicity is associated with improved treatment response.
    Leuk Lymphoma. 2021;62:2915-2920.
    PubMed     Abstract available

  95. MEGHEREA O, Janes C, Kowalski A, Baron J, et al
    Real-world assessment of isocitrate dehydrogenase inhibitor-associated differentiation syndrome.
    Leuk Lymphoma. 2021;62:3219-3225.
    PubMed     Abstract available

  96. SHIMONY S, Bar-Sever E, Berger T, Itchaki G, et al
    Late onset neutropenia after rituximab and obinutuzumab treatment - characteristics of a class-effect toxicity.
    Leuk Lymphoma. 2021;62:2921-2927.
    PubMed     Abstract available

    November 2021
  97. PRZESPOLEWSKI AC, Portwood S, Wang ES
    Targeting acute myeloid leukemia through multimodal immunotherapeutic approaches.
    Leuk Lymphoma. 2021 Nov 25:1-10. doi: 10.1080/10428194.2021.1992614.
    PubMed     Abstract available

  98. PALMIERI R, Buccisano F, Arena V, Irno Consalvo MA, et al
    CD34 + CD38-CLL1+ leukemic stem cells persistence measured by multiparametric flow cytometry is a biomarker of poor prognosis in adult patients with acute myeloid leukemia.
    Leuk Lymphoma. 2021 Nov 21:1-5. doi: 10.1080/10428194.2021.2005042.

  99. KHANAL N, Shostrom V, Dhakal P, Upadhyay Banskota S, et al
    Determinants of ten-year overall survival of acute myeloid leukemia: a large national cancer database analysis.
    Leuk Lymphoma. 2021 Nov 17:1-7. doi: 10.1080/10428194.2021.2005046.
    PubMed     Abstract available

  100. YUE X, Hincapie AL, Li Y, Guo JJ, et al
    Safety and cost-effectiveness of ponatinib versus other tyrosine kinase inhibitors as second-line therapy in patients with chronic myeloid leukemia in the United States.
    Leuk Lymphoma. 2021 Nov 15:1-9. doi: 10.1080/10428194.2021.2002320.
    PubMed     Abstract available

  101. JADERSTEN M, Boriskina K, Lindholm C, Westrom S, et al
    Limited benefit in patients with MDS receiving venetoclax and azacitidine as a bridge to allogeneic stem cell transplantation.
    Leuk Lymphoma. 2021 Nov 15:1-4. doi: 10.1080/10428194.2021.2002319.

  102. HALPERN AB, Estey EH
    More general incorporation of hemoglobin level into response criteria for myelodysplastic syndrome and acute myeloid leukemia with increase in minimum red cell transfusion levels.
    Leuk Lymphoma. 2021 Nov 8:1-4. doi: 10.1080/10428194.2021.1999446.

  103. ZEIDAN AM, Qi CZ, Yang H, Garnham A, et al
    Gilteritinib vs salvage chemotherapy in FLT3-mutated acute myeloid leukemia: number needed to treat for clinical outcomes per a secondary analysis of the ADMIRAL trial.
    Leuk Lymphoma. 2021 Nov 8:1-3. doi: 10.1080/10428194.2021.2001467.

  104. DA CUNHA-BANG C, Kirkby NS, Friis-Hansen L, Niemann CU, et al
    Serological response following vaccination with BNT162b2 mRNA in patients with chronic lymphocytic leukemia.
    Leuk Lymphoma. 2021 Nov 2:1-3. doi: 10.1080/10428194.2021.1973673.

  105. ARUMUGAM JR, Bommannan K, Radhakrishnan V, Sagar TG, et al
    Immunophenotypic expression and immunomodulation in minimal residual disease analysis of pediatric B acute lymphoblastic leukemia by high sensitive flow cytometry.
    Leuk Lymphoma. 2021 Nov 2:1-9. doi: 10.1080/10428194.2021.1992755.
    PubMed     Abstract available

  106. RIDGE SM, Whiteley AE, Yao H, Price TT, et al
    Pan-PI3Ki targets multiple B-ALL microenvironment interactions that fuel systemic and CNS relapse.
    Leuk Lymphoma. 2021;62:2690-2702.
    PubMed     Abstract available

  107. SOARE DS, Radu E, Dumitru I, Vladareanu AM, et al
    Quantitative analyses of CD7, CD33, CD34, CD56, and CD123 within the FLT3-ITD/NPM1-MUT myeloblastic/monocytic bulk AML blastic populations.
    Leuk Lymphoma. 2021;62:2716-2726.
    PubMed     Abstract available

  108. PATNAIK MM, Mughal TI, Brooks C, Lindsay R, et al
    Targeting CD123 in hematologic malignancies: identifying suitable patients for targeted therapy.
    Leuk Lymphoma. 2021;62:2568-2586.
    PubMed     Abstract available

    October 2021
  109. ALDOSS I, Clark M, Marcucci G, Forman SJ, et al
    Donor derived leukemia in allogeneic transplantation.
    Leuk Lymphoma. 2021 Oct 29:1-8. doi: 10.1080/10428194.2021.1929966.
    PubMed     Abstract available

  110. REX MR, Williams R, Birsoy K, Ta Llman MS, et al
    Targeting mitochondrial metabolism in acute myeloid leukemia.
    Leuk Lymphoma. 2021 Oct 27:1-8. doi: 10.1080/10428194.2021.1992759.
    PubMed     Abstract available

  111. GHIUZELI CM, Styblo M, Saunders J, Calabro A, et al
    The pharmacokinetics of therapeutic arsenic trioxide in acute promyelocytic leukemia patients.
    Leuk Lymphoma. 2021 Oct 25:1-11. doi: 10.1080/10428194.2021.1978084.
    PubMed     Abstract available

  112. TONG WH
    Comment on 'asparaginase activities during intensified treatment with pegylated E. coli asparaginase in adults with newly diagnosed acute lymphoblastic leukemia'.
    Leuk Lymphoma. 2021 Oct 22:1-2. doi: 10.1080/10428194.2021.1992760.

  113. CHEN M, Fu M, Wang A, Wu X, et al
    Cytoplasmic CD79a is a promising biomarker for B lymphoblastic leukemia follow up post CD19 CAR-T therapy.
    Leuk Lymphoma. 2021 Oct 21:1-9. doi: 10.1080/10428194.2021.1980214.
    PubMed     Abstract available

  114. GJAERDE LK, Rank CU, Andersen MK, Jakobsen LH, et al
    Improved survival after allogeneic transplantation for acute lymphoblastic leukemia in adults: a Danish population-based study.
    Leuk Lymphoma. 2021 Oct 21:1-10. doi: 10.1080/10428194.2021.1992620.
    PubMed     Abstract available

  115. RAMOS PEREZ JM, Patel KP, Loghavi S, Garcia-Manero G, et al
    Value of measurable residual disease monitoring in patients with acute promyelocytic leukemia in the era of frontline 'chemotherapy-free' therapy.
    Leuk Lymphoma. 2021 Oct 20:1-4. doi: 10.1080/10428194.2021.1992757.
    PubMed     Abstract available

  116. DOMENECH C, Plesa A, Tourette A, Bertrand Y, et al
    Prognostic impact of cN-III mRNA expression on overall survival and drug sensitivity in pediatric leukemia.
    Leuk Lymphoma. 2021 Oct 18:1-6. doi: 10.1080/10428194.2021.1992616.

  117. LI S, Ji Y, Peng Y, Kota V, et al
    Patient characteristics, treatment patterns, and mortality in elderly patients newly diagnosed with acute myeloid leukemia meeting ineligibility criteria for high intensity chemotherapy.
    Leuk Lymphoma. 2021 Oct 13:1-11. doi: 10.1080/10428194.2021.1973669.
    PubMed     Abstract available

  118. COCHRANE T, Enrico A, Gomez-Almaguer D, Hadjiev E, et al
    Impact of venetoclax monotherapy on the quality of life of patients with relapsed or refractory chronic lymphocytic leukemia: results from the phase 3b VENICE II trial.
    Leuk Lymphoma. 2021 Oct 11:1-11. doi: 10.1080/10428194.2021.1986217.
    PubMed     Abstract available

  119. AGIUS R, Parviz M, Niemann CU
    Artificial intelligence models in chronic lymphocytic leukemia - recommendations toward state-of-the-art.
    Leuk Lymphoma. 2021 Oct 6:1-14. doi: 10.1080/10428194.2021.1973672.
    PubMed     Abstract available

  120. XUE S, Zhang Y, Liu F, Huang W, et al
    Olaparib combined with chemotherapy for treatment of T-cell acute lymphoblastic leukemia relapse after unrelated umbilical cord blood transplantation.
    Leuk Lymphoma. 2021 Oct 5:1-5. doi: 10.1080/10428194.2021.1984453.

  121. NACHMIAS B, Rund D
    p53 in Acute Myeloid Leukemia-Still a significant other.
    Leuk Lymphoma. 2021 Oct 5:1-3. doi: 10.1080/10428194.2021.1988592.

  122. LEE Y, Yun J, Jeong D, Ryu S, et al
    Genetic profile of primary plasma cell leukemia in Korea: comparison with plasma cell myeloma.
    Leuk Lymphoma. 2021 Oct 1:1-10. doi: 10.1080/10428194.2021.1983568.
    PubMed     Abstract available

    The tools to choose: applying indirect treatment comparisons to the selection of frontline targeted therapy for CLL.
    Leuk Lymphoma. 2021;62:2299-2302.

  124. ALHALLAK K, de la Puente P, Jeske A, Sun J, et al
    3D tissue engineered plasma cultures support leukemic proliferation and induces drug resistance.
    Leuk Lymphoma. 2021;62:2457-2465.
    PubMed     Abstract available

  125. JACOBY MA, Finn L, Emadi A, Saba NS, et al
    Frequency of infusion-related reactions with CPX-351 treatment in an observational study in adults with newly diagnosed therapy-related AML or AML with myelodysplasia-related changes (AML-MRC).
    Leuk Lymphoma. 2021;62:2539-2542.

  126. RAMAN I, Pasricha SR, Prince HM, Yannakou CK, et al
    Management of hydroxyurea resistant or intolerant polycythemia vera.
    Leuk Lymphoma. 2021;62:2310-2319.
    PubMed     Abstract available

  127. SHIMONY S, Yeshurun M, Wolach O, Ram R, et al
    Post-transplantation maintenance with sorafenib or midostaurin for FLT3 positive AML patients - a multicenter retrospective observational study.
    Leuk Lymphoma. 2021;62:2475-2481.
    PubMed     Abstract available

    September 2021
  128. VAN BESIEN K, Gomez-Arteaga A
    Maintenance therapy after allogeneic transplant for acute myeloid leukemia: great expectations.
    Leuk Lymphoma. 2021 Sep 29:1-4. doi: 10.1080/10428194.2021.1980787.

  129. MALPICA L, Castro D, Enriquez DJ, Oviedo-Pecho R, et al
    An international, multicenter, retrospective study on the positive impact of cutaneous involvement on the clinical outcome of adult T-cell leukemia/lymphoma.
    Leuk Lymphoma. 2021 Sep 29:1-11. doi: 10.1080/10428194.2021.1984455.
    PubMed     Abstract available

  130. CHAJUWAN T, Kansuwan P, Kobbuaklee S, Chanswangphuwana C, et al
    Characteristics and clinical correlation of TIM-3 and PD-1/PD-L1 expressions in leukemic cells and tumor microenvironment in newly diagnosed acute myeloid leukemia.
    Leuk Lymphoma. 2021 Sep 29:1-7. doi: 10.1080/10428194.2021.1984454.
    PubMed     Abstract available

  131. ALDERUCCIO JP, Lossos IS
    NOTCH signaling in the pathogenesis of splenic marginal zone lymphoma-opportunities for therapy.
    Leuk Lymphoma. 2021 Sep 29:1-12. doi: 10.1080/10428194.2021.1984452.
    PubMed     Abstract available

  132. STAHL M, Tallman MS, Goldberg AD
    Measurable residual disease negativity in acute myeloid leukemia: the destination may matter more than the journey.
    Leuk Lymphoma. 2021 Sep 14:1-2. doi: 10.1080/10428194.2021.1929967.

  133. PATEL SA, Lloyd MR, Cerny J, Shi Q, et al
    Clinico-genomic profiling and clonal dynamic modeling of TP53-aberrant myelodysplastic syndrome and acute myeloid leukemia.
    Leuk Lymphoma. 2021 Sep 9:1-13. doi: 10.1080/10428194.2021.1957869.
    PubMed     Abstract available

  134. BANKAR A, Lipton JH
    Association of creatine kinase elevation with clinical outcomes in chronic myeloid leukemia: a retrospective cohort study.
    Leuk Lymphoma. 2021 Sep 8:1-10. doi: 10.1080/10428194.2021.1971219.
    PubMed     Abstract available

  135. KHULLAR K, Plascak JJ, Parikh RR
    Acute lymphoblastic leukemia (ALL) in adults: disparities in treatment intervention based on access to treatment facility.
    Leuk Lymphoma. 2021 Sep 8:1-9. doi: 10.1080/10428194.2021.1975187.
    PubMed     Abstract available

  136. JACOBS JW, Ramaswamy R, States V, Reppucci J, et al
    Chronic myeloid leukemia with pure erythroid leukemia blast crisis.
    Leuk Lymphoma. 2021 Sep 6:1-5. doi: 10.1080/10428194.2021.1975191.
    PubMed     Abstract available

  137. XU DM, Yu WJ, Xie L, Zhang ZW, et al
    The diagnostic profile of rare acute myelomegakaryoblastic leukemia.
    Leuk Lymphoma. 2021 Sep 3:1-8. doi: 10.1080/10428194.2021.1955878.
    PubMed     Abstract available

  138. VENUGOPAL S, Maiti A, DiNardo CD, Qiao W, et al
    Prognostic impact of conventional cytogenetics in acute myeloid leukemia treated with venetoclax and decitabine.
    Leuk Lymphoma. 2021 Sep 3:1-5. doi: 10.1080/10428194.2021.1973675.

  139. DUPUY H, Dussiau C, Bidet A, Sauvezie M, et al
    Looking for somatic mutations in UBA1 in patients with chronic myelomonocytic leukemia associated with systemic inflammation and autoimmune diseases.
    Leuk Lymphoma. 2021 Sep 3:1-3. doi: 10.1080/10428194.2021.1973674.

    August 2021
  140. HANSENNE A, Camboni A, Van Den Neste E, Bailly S, et al
    Richter transformation heralded by EBV reactivation during ibrutinib therapy for chronic lymphocytic leukemia.
    Leuk Lymphoma. 2021 Aug 25:1-3. doi: 10.1080/10428194.2021.1964023.

  141. PATEL SA, Dalela D, Fan AC, Lloyd MR, et al
    Niche-directed therapy in acute myeloid leukemia: optimization of stem cell competition for niche occupancy.
    Leuk Lymphoma. 2021 Aug 19:1-9. doi: 10.1080/10428194.2021.1966779.
    PubMed     Abstract available

  142. ZERBIT J, Tamburini J, Goldwirt L, Decroocq J, et al
    Asciminib and ponatinib combination in Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Leuk Lymphoma. 2021 Aug 18:1-4. doi: 10.1080/10428194.2021.1966787.

  143. WANG J, Yang L, Dao FT, Wang YZ, et al
    Prognostic significance of TIM-3 expression pattern at diagnosis in patients with t(8;21) acute myeloid leukemia.
    Leuk Lymphoma. 2021 Aug 18:1-10. doi: 10.1080/10428194.2021.1966785.
    PubMed     Abstract available

  144. KIMBLE EL, Cassaday RD
    Antibody and cellular immunotherapies for acute lymphoblastic leukemia in adults.
    Leuk Lymphoma. 2021 Aug 17:1-15. doi: 10.1080/10428194.2021.1964022.
    PubMed     Abstract available

  145. SOREL N, Raimbault A, Brizard F, Depaire T, et al
    Identification and genetic characterization of a NUP98-HHEX molecular rearrangement in a pediatric acute myeloid leukemia.
    Leuk Lymphoma. 2021 Aug 17:1-5. doi: 10.1080/10428194.2021.1966784.

  146. MITROVIC M, Pantic N, Sabljic N, Vucic M, et al
    Acute leukemia and SARS-CoV-2 infection: clinical characteristics and risk factors for mortality.
    Leuk Lymphoma. 2021 Aug 13:1-5. doi: 10.1080/10428194.2021.1964026.
    PubMed     Abstract available

  147. WOYACH J, Tedeschi A, Munir T, Siddiqi T, et al
    Using ibrutinib in earlier lines of treatment results in better outcomes for patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.
    Leuk Lymphoma. 2021 Aug 13:1-5. doi: 10.1080/10428194.2021.1957871.

  148. ABBAS HA, Reville PK, Geppner A, Rausch CR, et al
    Clinical and molecular characterization of myeloid sarcoma without medullary leukemia.
    Leuk Lymphoma. 2021 Aug 12:1-9. doi: 10.1080/10428194.2021.1961235.
    PubMed     Abstract available

  149. NEE A, Lipton JH, Kim DDH
    Early prediction of stable MR(4.5) by depth of molecular response at 6 months in patients with chronic myeloid leukemia treated with frontline imatinib.
    Leuk Lymphoma. 2021 Aug 11:1-8. doi: 10.1080/10428194.2021.1961234.
    PubMed     Abstract available

  150. CORDOVA-SERRANO RD, Almanza-Huante E, Fernandez-Sanchez E, Hernandez-Alcantara A, et al
    Central nervous system (CNS) involvement has an adverse impact on survival in newly diagnosed adult acute lymphoblastic leukemia (ALL) assessed by flow cytometry.
    Leuk Lymphoma. 2021 Aug 9:1-7. doi: 10.1080/10428194.2021.1957872.
    PubMed     Abstract available

  151. KUTTIKRISHNAN S, Prabhu KS, Khan AQ, Alali FQ, et al
    Thiostrepton inhibits growth and induces apoptosis by targeting FoxM1/SKP2/MTH1 axis in B-precursor acute lymphoblastic leukemia cells.
    Leuk Lymphoma. 2021 Aug 9:1-11. doi: 10.1080/10428194.2021.1957873.
    PubMed     Abstract available

  152. AL-HADAD SA, Al-Jadiry MF, Ghali HH, Al-Badri SAF, et al
    Treatment of childhood acute lymphoblastic leukemia in Iraq: a 17-year experience from a single center.
    Leuk Lymphoma. 2021 Aug 6:1-10. doi: 10.1080/10428194.2021.1961237.
    PubMed     Abstract available

  153. YANADA M, Mizuno S, Yamasaki S, Harada K, et al
    Difference in outcomes following allogeneic hematopoietic cell transplantation for patients with acute myeloid leukemia and myelodysplastic syndromes.
    Leuk Lymphoma. 2021 Aug 4:1-9. doi: 10.1080/10428194.2021.1961242.
    PubMed     Abstract available

  154. COPPOLA PE, Broccoli A, Argnani L, Casadei B, et al
    Rapid but reversible progression and transformation of chronic lymphocytic leukemia after temporary ibrutinib discontinuation due to off-target toxicity: two interesting cases.
    Leuk Lymphoma. 2021 Aug 4:1-4. doi: 10.1080/10428194.2021.1961241.

  155. RAMIREZ-LOPEZ A, Lazaro Del Campo P, Humala K, De la Cruz Benito B, et al
    Lessons learned for successful treatment of AML in the second wave of COVID-19 outbreak.
    Leuk Lymphoma. 2021;62:2034-2036.

  156. ROSSO A, Juliusson G, Lorenz F, Lehmann S, et al
    Is there an impact of measurable residual disease as assessed by multiparameter flow cytometry on survival of AML patients treated in clinical practice? A population-based study.
    Leuk Lymphoma. 2021;62:1973-1981.
    PubMed     Abstract available

  157. NAUR TMH, Jakobsen LH, Roug AS, El-Galaly TC, et al
    Treatment intensity and survival trends among real-world elderly AML patients diagnosed in the period 2001-2016: a Danish nationwide cohort study.
    Leuk Lymphoma. 2021;62:2014-2017.

    July 2021
  158. WAN CL, Zou JY, Qiao M, Yin J, et al
    Venetoclax combined with azacitidine as an effective and safe salvage regimen for relapsed or refractory T-cell acute lymphoblastic leukemia: a case series.
    Leuk Lymphoma. 2021 Jul 29:1-4. doi: 10.1080/10428194.2021.1957876.

  159. KOUTROUMANI M, Laidou S, Kotta K, Stamatopoulos K, et al
    TAp63 and BCL2 expression are co-affected by cell-extrinsic signals in chronic lymphocytic leukemia.
    Leuk Lymphoma. 2021 Jul 29:1-4. doi: 10.1080/10428194.2021.1957870.

  160. SWEET K, Bhatnagar B, Dohner H, Donnellan W, et al
    A 2:1 randomized, open-label, phase II study of selinexor vs. physician's choice in older patients with relapsed or refractory acute myeloid leukemia.
    Leuk Lymphoma. 2021 Jul 29:1-12. doi: 10.1080/10428194.2021.1950706.
    PubMed     Abstract available

  161. EL HUSSEIN S, Wang W, Wang SA, Loghavi S, et al
    Blastic plasmacytoid dendritic cell neoplasm with history of myeloma and concomitant acute undifferentiated leukemia: Illustration of morphologic and immunophenotypic challenges of an emerging phenomenon.
    Leuk Lymphoma. 2021 Jul 24:1-4. doi: 10.1080/10428194.2021.1957878.

  162. PALANQUES-PASTOR T, Megias-Vericat JE, Martinez P, Lopez Lorenzo JL, et al
    Characteristics, clinical outcomes, and risk factors of SARS-COV-2 infection in adult acute myeloid leukemia patients: experience of the PETHEMA group.
    Leuk Lymphoma. 2021 Jul 22:1-11. doi: 10.1080/10428194.2021.1948031.
    PubMed     Abstract available

  163. WEBSTER JA, Yogarajah M, Zahurak M, Symons H, et al
    A phase II study of azacitidine in combination with granulocyte-macrophage colony-stimulating factor as maintenance treatment, after allogeneic blood or marrow transplantation in patients with poor-risk acute myeloid leukemia (AML) or myelodysplastic
    Leuk Lymphoma. 2021 Jul 21:1-11. doi: 10.1080/10428194.2021.1948029.
    PubMed     Abstract available

  164. DUNN KA, Forbrigger Z, Connors J, Rahman M, et al
    Gut bacterial gene changes following pegaspargase treatment in pediatric patients with acute lymphoblastic leukemia.
    Leuk Lymphoma. 2021 Jul 19:1-12. doi: 10.1080/10428194.2021.1953006.
    PubMed     Abstract available

  165. BEYAN C
    Mean platelet volume may not be a predictive and prognostic marker in patients with acute myeloid leukemia.
    Leuk Lymphoma. 2021 Jul 14:1. doi: 10.1080/10428194.2021.1953017.

  166. GAO J, Fu L, Lu X, Sukhanova M, et al
    Mast cell sarcoma transdifferentiated from clonally-related T-lymphoblastic leukemia upon acquisition of TP53 mutation and genetic complexity.
    Leuk Lymphoma. 2021 Jul 14:1-4. doi: 10.1080/10428194.2021.1950710.

  167. PAGNANO KB, Peralta EH, Navarro JR, David Salas LDR, et al
    COVID-19 in chronic myeloid leukemia patients in Latin America.
    Leuk Lymphoma. 2021 Jul 13:1-7. doi: 10.1080/10428194.2021.1950709.
    PubMed     Abstract available

  168. JIANG H, Liu XH, Kong J, Wang J, et al
    Interferon-alpha as maintenance therapy can significantly reduce relapse in patients with favorable-risk acute myeloid leukemia.
    Leuk Lymphoma. 2021 Jul 1:1-8. doi: 10.1080/10428194.2021.1948027.
    PubMed     Abstract available

  169. JINDAL N, Lad DP, Malhotra P, Prakash G, et al
    Randomized controlled trial of individualized, low dose, fixed duration lenalidomide maintenance versus observation after frontline chemo-immunotherapy in CLL.
    Leuk Lymphoma. 2021;62:1674-1681.
    PubMed     Abstract available

  170. WITTMANN DAYAGI T, Sherman G, Bielorai B, Adam E, et al
    Characteristics and risk factors of infections following CD28-based CD19 CAR-T cells.
    Leuk Lymphoma. 2021;62:1692-1701.
    PubMed     Abstract available

    June 2021
  171. STAHL M, Narendra V, Jee J, Derkach A, et al
    Neutropenia in adult acute myeloid leukemia patients represents a powerful risk factor for COVID-19 related mortality.
    Leuk Lymphoma. 2021 Jun 28:1-9. doi: 10.1080/10428194.2021.1885664.
    PubMed     Abstract available

  172. LEPRETRE S, Touboul C, Flinois A, Kutikova L, et al
    Quality of life in adults with acute lymphoblastic leukemia in France: results from a French cross-sectional study.
    Leuk Lymphoma. 2021 Jun 24:1-11. doi: 10.1080/10428194.2021.1941924.
    PubMed     Abstract available

  173. YOSHIMOTO G, Mori Y, Kato K, Odawara J, et al
    Azacitidine for the treatment of patients with relapsed acute myeloid leukemia after allogeneic stem cell transplantation.
    Leuk Lymphoma. 2021 Jun 23:1-10. doi: 10.1080/10428194.2021.1941937.
    PubMed     Abstract available

  174. SINGH J, Facey A, O'Malley F, Ryland GL, et al
    Cryptic molecular lesion in acute promyelocytic leukemia with negative initial FISH.
    Leuk Lymphoma. 2021 Jun 21:1-3. doi: 10.1080/10428194.2021.1941935.

  175. HADJIAGGELIDOU C, Douganiotis G, Tsirou K, Verrou E, et al
    A rare case of autoimmune hemolytic anemia during venetoclax therapy for relapsed chronic lymphocytic leukemia.
    Leuk Lymphoma. 2021 Jun 21:1-3. doi: 10.1080/10428194.2021.1941932.

  176. RAMKISSOON LA, Buhlinger K, Nichols A, Coombs CC, et al
    Clonal evolution of Philadelphia chromosome in acute myeloid leukemia after enasidenib treatment.
    Leuk Lymphoma. 2021 Jun 21:1-4. doi: 10.1080/10428194.2021.1941928.

  177. BOLUDA B, Martinez-Cuadron D, Algarra L, Cano I, et al
    Evolving patterns of care and outcomes in relapsed/refractory FLT3 mutated acute myeloid leukemia adult patients.
    Leuk Lymphoma. 2021 Jun 14:1-10. doi: 10.1080/10428194.2021.1938031.
    PubMed     Abstract available

  178. CHIHARA D, Larson MC, Robinson DP, Thompson CA, et al
    Body mass index and survival of patients with lymphoma.
    Leuk Lymphoma. 2021 Jun 14:1-8. doi: 10.1080/10428194.2021.1929956.
    PubMed     Abstract available

  179. KHAZAL S, Kebriaei P
    Hematopoietic cell transplantation for acute lymphoblastic leukemia: review of current indications and outcomes.
    Leuk Lymphoma. 2021 Jun 3:1-14. doi: 10.1080/10428194.2021.1933475.
    PubMed     Abstract available

  180. STUBBINS RJ, Maksakov IA, Sanford DS, Rouhi A, et al
    Mitochondrial metabolism: powering new directions in acute myeloid leukemia.
    Leuk Lymphoma. 2021 Jun 1:1-11. doi: 10.1080/10428194.2021.1910685.
    PubMed     Abstract available

  181. BOULLAND ML, Vic S, Thonier F, Ganard M, et al
    Reliable IGHV status assessment by next generation sequencing in routine practice for chronic lymphocytic leukemia.
    Leuk Lymphoma. 2021 Jun 1:1-4. doi: 10.1080/10428194.2021.1933476.

  182. LADHA A, Hui G, Cheung E, Berube C, et al
    Routine use of gemtuzumab ozogamicin in 7 + 3-based inductions for all 'non-adverse' risk AML.
    Leuk Lymphoma. 2021;62:1510-1513.

  183. SENAPATI J, Dhawan R, Aggarwal M, Kumar P, et al
    Venetoclax and azacitidine (VenAZA) combination therapy in young unfit patients with AML: a perspective from a developing country.
    Leuk Lymphoma. 2021;62:1514-1517.

  184. QU S, Jia Y, Wang H, Ai X, et al
    STAT3 and STAT5B mutations have unique distribution in T-cell large granular lymphocyte proliferations and advanced myeloid neoplasms.
    Leuk Lymphoma. 2021;62:1506-1509.

    May 2021
  185. YURKIEWICZ IR, Coutre S, Ghesquieres H, Pastan I, et al
    Moxetumomab pasudotox as re-treatment for heavily-pretreated relapsed hairy cell leukemia.
    Leuk Lymphoma. 2021 May 25:1-3. doi: 10.1080/10428194.2021.1929959.

  186. CUMBO C, Tota G, De Grassi A, Anelli L, et al
    RUNX1 gene alterations characterized by allelic preference in adult acute myeloid leukemia.
    Leuk Lymphoma. 2021 May 24:1-5. doi: 10.1080/10428194.2021.1929960.

  187. SHARMA P, Rana S, Virk H, Sachdeva MUS, et al
    The frequency, hematological characteristics, and end-of induction residual disease in B-acute lymphoblastic leukemia with BCR-ABL1-like chimeric gene fusions in a high-risk cohort from India.
    Leuk Lymphoma. 2021 May 24:1-5. doi: 10.1080/10428194.2021.1929964.

  188. JIN H, Zhu Y, Hong M, Wu Y, et al
    Co-occurrence of KIT and NRAS mutations defines an adverse prognostic core-binding factor acute myeloid leukemia.
    Leuk Lymphoma. 2021 May 24:1-10. doi: 10.1080/10428194.2021.1919660.
    PubMed     Abstract available

  189. BAZINET A, Rys RN, Barry A, Greenwood CMT, et al
    A 10-color flow cytometry panel for diagnosis and minimal residual disease in chronic lymphocytic leukemia.
    Leuk Lymphoma. 2021 May 21:1-8. doi: 10.1080/10428194.2021.1919658.
    PubMed     Abstract available

  190. TIGLIOGLU M, Albayrak M, Dogan S, Yilmaz F, et al
    Mean platelet volume is a predictive and prognostic marker for patients with acute myeloid leukemia: a two-center retrospective analysis.
    Leuk Lymphoma. 2021 May 20:1-7. doi: 10.1080/10428194.2021.1929962.
    PubMed     Abstract available

  191. HANDL S, von Heydebrand F, Voelkl S, Oostendorp RAJ, et al
    Immune modulatory effects of Idelalisib in stromal cells of chronic lymphocytic leukemia.
    Leuk Lymphoma. 2021 May 17:1-11. doi: 10.1080/10428194.2021.1927019.
    PubMed     Abstract available

  192. LIANG D, Wei C, Zhang X, Yang J, et al
    Efficacy of lenalidomide for relapsed or refractory T lymphoblastic lymphoma/leukemia after allogeneic hematopoietic stem cell transplantation.
    Leuk Lymphoma. 2021 May 17:1-5. doi: 10.1080/10428194.2021.1919665.

  193. KUROSAWA S, Kaito S, Uchida N, Fukuda T, et al
    Allogeneic hematopoietic stem cell transplantation for adult patients with B-cell acute lymphoblastic leukemia with high hyperdiploidy: a retrospective nationwide study.
    Leuk Lymphoma. 2021 May 12:1-7. doi: 10.1080/10428194.2021.1924374.
    PubMed     Abstract available

  194. DAVIDS MS, Telford C, Abhyankar S, Waweru C, et al
    Matching-adjusted indirect comparisons of safety and efficacy of acalabrutinib versus other targeted therapies in patients with treatment-naive chronic lymphocytic leukemia.
    Leuk Lymphoma. 2021 May 6:1-16. doi: 10.1080/10428194.2021.1913144.
    PubMed     Abstract available

  195. ADNAN-AWAD S, Kankainen M, Mustjoki S
    Mutational landscape of chronic myeloid leukemia: more than a single oncogene leukemia.
    Leuk Lymphoma. 2021 May 4:1-15. doi: 10.1080/10428194.2021.1894652.
    PubMed     Abstract available

  196. MARQUES-PIUBELLI ML, Schlette EJ, Khoury JD, Furqan F, et al
    Expression of BCL2 alternative proteins and association with outcome in CLL patients treated with venetoclax.
    Leuk Lymphoma. 2021;62:1129-1135.
    PubMed     Abstract available

    April 2021
  197. WALLWITZ J, Aigner P, Stoiber D
    Tumor suppressors in acute myeloid leukemia.
    Leuk Lymphoma. 2021 Apr 30:1-11. doi: 10.1080/10428194.2021.1907372.
    PubMed     Abstract available

  198. WANG M, Wang R, Wang H, Chen C, et al
    Difference in gene mutation profile in patients with refractory/relapsed versus newly diagnosed acute myeloid leukemia based on targeted next-generation sequencing.
    Leuk Lymphoma. 2021 Apr 29:1-12. doi: 10.1080/10428194.2021.1919661.
    PubMed     Abstract available

  199. WANG N, Yuan L, Jing Y, Fan K, et al
    Double minute chromosomes in acute myeloid leukemia and myelodysplastic syndromes are associated with complex karyotype, monosomal karyotype, TP53 deletion, and TP53 mutations.
    Leuk Lymphoma. 2021 Apr 27:1-9. doi: 10.1080/10428194.2021.1919663.
    PubMed     Abstract available

  200. REES MJ, Wu S, Mokoonlall M, Dix CHK, et al
    The real-world tolerability and efficacy of asparaginase in adults aged 40 years and older with Philadelphia-negative acute lymphoblastic leukemia.
    Leuk Lymphoma. 2021 Apr 26:1-3. doi: 10.1080/10428194.2021.1919666.

  201. ZHAN M, Chen ZB, Ding CC, Qu Q, et al
    Machine learning to predict high-dose methotrexate-related neutropenia and fever in children with B-cell acute lymphoblastic leukemia.
    Leuk Lymphoma. 2021 Apr 26:1-12. doi: 10.1080/10428194.2021.1913140.
    PubMed     Abstract available

  202. GUPTA A, Gill S
    CAR-T cell persistence in the treatment of leukemia and lymphoma.
    Leuk Lymphoma. 2021 Apr 19:1-13. doi: 10.1080/10428194.2021.1913146.
    PubMed     Abstract available

  203. WALKER KL, Rinella SP, Hess NJ, Turicek DP, et al
    CXCR4 allows T cell acute lymphoblastic leukemia to escape from JAK1/2 and BCL2 inhibition through CNS infiltration.
    Leuk Lymphoma. 2021 Apr 11:1-11. doi: 10.1080/10428194.2021.1910684.
    PubMed     Abstract available

  204. FAZIO F, Quintini M, Carmosino I, Matteucci C, et al
    New dead/H-box helicase gene (ddx41) mutation in an Italian family with recurrent leukemia.
    Leuk Lymphoma. 2021 Apr 9:1-4. doi: 10.1080/10428194.2021.1910689.

  205. BENITEZ LL, Perissinotti AJ, Rausch CR, Klaus J, et al
    Multicenter comparison of high-dose cytarabine-based regimens versus liposomal daunorubicin and cytarabine (CPX-351) in patients with secondary acute myeloid leukemia.
    Leuk Lymphoma. 2021 Apr 8:1-9. doi: 10.1080/10428194.2021.1907378.
    PubMed     Abstract available

  206. PASIC I, Paulson K, Dozois G, Schultz KR, et al
    Inferior outcomes with reduced intensity conditioning followed by allogeneic hematopoietic cell transplantation in fit individuals with acute lymphoblastic leukemia: a Canadian single-center study and a comparison to registry data.
    Leuk Lymphoma. 2021 Apr 8:1-9. doi: 10.1080/10428194.2021.1910688.
    PubMed     Abstract available

  207. HIDALGO-GOMEZ G, Palacio-Garcia C, Gallur L, Blanco A, et al
    Is acute lymphoblastic leukemia with mature B-cell phenotype and KMT2A rearrangements a new entity? A systematic review and meta-analysis.
    Leuk Lymphoma. 2021 Apr 7:1-9. doi: 10.1080/10428194.2021.1907375.
    PubMed     Abstract available

  208. JOBSON D, McCormack CJ, Hiscutt E, Tam C, et al
    Severe treatment-resistant autoimmune haemolytic anaemia following ipilimumab in a patient with metastatic melanoma and CLL.
    Leuk Lymphoma. 2021;62:992-994.

  209. HARROP S, Polliack A, Tam CS
    Chronic lymphoproliferative disorders and secondary cancers in the era of purine analogues and beyond.
    Leuk Lymphoma. 2021;62:771-778.
    PubMed     Abstract available

  210. PACOUREAU L, De Menthon M, Boytchev I, Lazure T, et al
    Severe ulcerative gastrointestinal toxicity following ibrutinib therapy: two case studies.
    Leuk Lymphoma. 2021;62:984-987.

    March 2021
  211. BONOMETTI A, Lobascio G, Boveri E, Cesari S, et al
    Acute megakaryoblastic leukemia with a novel GATA1 mutation in a second trimester stillborn fetus with trisomy 21.
    Leuk Lymphoma. 2021 Mar 30:1-4. doi: 10.1080/10428194.2021.1907377.

  212. EPSTEIN-PETERSON ZD, Ganesan N, Barker JN, Drullinsky PR, et al
    Outcomes of adult T-Cell leukemia/lymphoma with allogeneic stem cell transplantation: single-institution experience.
    Leuk Lymphoma. 2021 Mar 29:1-7. doi: 10.1080/10428194.2021.1897806.
    PubMed     Abstract available

  213. HOCHMAN MJ, Othus M, Walter RB, Shaw C, et al
    Effect of post-treatment MRD status on subsequent outcomes according to chemotherapy intensity in acute myeloid leukemia (AML).
    Leuk Lymphoma. 2021 Mar 22:1-4. doi: 10.1080/10428194.2021.1885658.

  214. ELITZUR S, Frank S, Goshen-Lago T, Barzilai-Birenboim S, et al
    Long-term ovarian reserve and fertility outcomes in female survivors of childhood acute lymphoblastic leukemia.
    Leuk Lymphoma. 2021 Mar 22:1-10. doi: 10.1080/10428194.2021.1901093.
    PubMed     Abstract available

  215. FULCHER J, Berardi P, Christou G, Villeneuve PJA, et al
    Nelarabine-containing regimen followed by daratumumab as an effective salvage therapy and bridge to allogeneic hematopoietic stem cell transplantation for primary refractory early T-cell precursor lymphoblastic leukemia.
    Leuk Lymphoma. 2021 Mar 21:1-3. doi: 10.1080/10428194.2021.1901097.

  216. BALAKRISHNA J, Basumallik N, Matulonis R, Scott D, et al
    Intensity of antigen expression reflects IGHV mutational status and Dohner-defined prognostic categories in chronic lymphocytic leukemia, monoclonal B-cell lymphocytosis, and small lymphocytic lymphoma.
    Leuk Lymphoma. 2021 Mar 18:1-12. doi: 10.1080/10428194.2021.1894641.
    PubMed     Abstract available

  217. DE CARVALHO AC, Ogawa CY Junior, De Camillis Rodrigues L, de Medeiros LS, et al
    Penicillium genus as a source for anti-leukemia compounds: an overview from 1984 to 2020.
    Leuk Lymphoma. 2021 Mar 18:1-15. doi: 10.1080/10428194.2021.1897804.
    PubMed     Abstract available

  218. PEPE S, Scalzulli E, Colafigli G, Di Prima A, et al
    Long-term follow-up of late chronic phase chronic myeloid leukemia patients treated with imatinib after interferon failure: a single center experience.
    Leuk Lymphoma. 2021 Mar 16:1-6. doi: 10.1080/10428194.2021.1901094.
    PubMed     Abstract available

  219. PETTERSSON L, Holmgren B, Juliusson G, Lazarevic VL, et al
    Mutational spectrum of de novo NPM1-mutated acute myeloid leukemia patients older than 75 years.
    Leuk Lymphoma. 2021 Mar 12:1-9. doi: 10.1080/10428194.2021.1894650.
    PubMed     Abstract available

  220. DHAKAL P, Lyden E, Rajasurya V, Zeidan AM, et al
    Early mortality and overall survival in acute promyelocytic leukemia: do real-world data match results of the clinical trials?
    Leuk Lymphoma. 2021 Mar 12:1-9. doi: 10.1080/10428194.2021.1894651.
    PubMed     Abstract available

  221. ARORA S, Vachhani P, Bachiashvili K, Jamy O, et al
    Venetoclax with chemotherapy in relapse/refractory early T-cell precursor acute lymphoblastic leukemia.
    Leuk Lymphoma. 2021 Mar 10:1-3. doi: 10.1080/10428194.2021.1897807.

  222. OTHUS M, Garcia-Manero G, Godwin J, Weick J, et al
    Associations between complete remission and 2- to 3-year survival following 7 + 3 induction for acute myeloid leukemia.
    Leuk Lymphoma. 2021 Mar 10:1-6. doi: 10.1080/10428194.2021.1885663.
    PubMed     Abstract available

  223. XU W, Ye L, Mei C, Zhou XP, et al
    Decitabine combined with low dose idarubicin and cytarabine (D-IA) followed by allo-HSCT improves acute myeloid leukemia and higher-risk myelodysplastic syndrome patient outcomes: results from a retrospective study.
    Leuk Lymphoma. 2021 Mar 7:1-18. doi: 10.1080/10428194.2021.1891230.
    PubMed     Abstract available

  224. MAFFEI R, Fiorcari S, Atene CG, Martinelli S, et al
    A single-tube multiplex method for monitoring mutations in cysteine 481 of Bruton Tyrosine Kinase (BTK) gene in chronic lymphocytic leukemia patients treated with ibrutinib.
    Leuk Lymphoma. 2021 Mar 4:1-6. doi: 10.1080/10428194.2021.1894643.

  225. DESAI S, Mo C, Gaglione EM, Yuan CM, et al
    Risk-adapted, ofatumumab-based chemoimmunotherapy and consolidation in treatment-naive chronic lymphocytic leukemia: a phase 2 study.
    Leuk Lymphoma. 2021 Mar 2:1-17. doi: 10.1080/10428194.2021.1888379.
    PubMed     Abstract available

  226. MARTINEZ-LOPEZ J, Mustjoki S, Porkka K, Klisovic RB, et al
    The safety and efficacy of dasatinib plus nivolumab in patients with previously treated chronic myeloid leukemia: results from a phase 1b dose-escalation study.
    Leuk Lymphoma. 2021 Mar 2:1-7. doi: 10.1080/10428194.2021.1889536.

  227. ROERDEN M, Marklin M, Salih HR, Bethge WA, et al
    Expression levels of HLA-DR in acute myeloid leukemia: implications for antigenicity and clinical outcome.
    Leuk Lymphoma. 2021 Mar 2:1-18. doi: 10.1080/10428194.2021.1885659.
    PubMed     Abstract available

  228. ATALLAH EL, Sadek I, Maegawa R, Cao X, et al
    Tyrosine kinase inhibitor therapy discontinuation in patients with chronic myeloid leukemia in chronic phase in the United States after clinical practice guideline updates.
    Leuk Lymphoma. 2021 Mar 1:1-14. doi: 10.1080/10428194.2021.1885656.
    PubMed     Abstract available

  229. TIMOFEEVA N, Gandhi V
    Metabolism meets apoptosis in AML.
    Leuk Lymphoma. 2021;62:514-516.

  230. CHEN NC, Borthakur G, Pemmaraju N
    Bromodomain and extra-terminal (BET) inhibitors in treating myeloid neoplasms.
    Leuk Lymphoma. 2021;62:528-537.
    PubMed     Abstract available

    February 2021
  231. FODIL S, Raffoux E, Dumas PY, Desbrosses Y, et al
    Data from French named patient program of quizartinib in relapsed/refractory acute myeloid leukemia.
    Leuk Lymphoma. 2021 Feb 17:1-7. doi: 10.1080/10428194.2021.1881505.

  232. KHAN S, Durairaj S, Phumphukhieo P, Holding S, et al
    Ibrutinib does not reverse disease- and treatment-related hypogammaglobulinaemia associated with chronic lymphocytic leukemia.
    Leuk Lymphoma. 2021 Feb 17:1-8. doi: 10.1080/10428194.2021.1885662.

  233. PRZESPOLEWSKI A, Muppidi MR, Freyer CW, Ji W, et al
    Cladribine, cytarabine, and GCSF with and without mitoxantrone (CLAG +/- M) is highly effective for poor risk acute myeloid leukemia with adverse karyotype and prior hypomethylating therapy.
    Leuk Lymphoma. 2021 Feb 16:1-6. doi: 10.1080/10428194.2021.1885654.

  234. RAMAN HS, Shanmugam V, Li J, Steensma DP, et al
    NPM1-mutant acute myeloid leukemia relapsing as acute lymphoblastic leukemia with clonal persistence of IDH1 mutation.
    Leuk Lymphoma. 2021 Feb 13:1-5. doi: 10.1080/10428194.2021.1881510.

  235. ROBOZ GJ, Desai P, Lee S, Ritchie EK, et al
    A dose escalation study of RO6870810/TEN-10 in patients with acute myeloid leukemia and myelodysplastic syndrome.
    Leuk Lymphoma. 2021 Feb 13:1-13. doi: 10.1080/10428194.2021.1881509.
    PubMed     Abstract available

  236. FREI CR, Le H, McHugh D, Ryan K, et al
    Outcomes in chronic lymphocytic leukemia patients on novel agents in the US Veterans Health Administration System.
    Leuk Lymphoma. 2021 Feb 11:1-14. doi: 10.1080/10428194.2021.1876863.
    PubMed     Abstract available

  237. BAK A, Skonieczka K, Jaskowiec A, Junkiert-Czarnecka A, et al
    Searching for germline mutations in the RUNX1 gene among Polish patients with acute myeloid leukemia.
    Leuk Lymphoma. 2021 Feb 10:1-9. doi: 10.1080/10428194.2021.1881503.
    PubMed     Abstract available

  238. MOSELEY A, Othus M, Garcia-Manero G, Appelbaum FR, et al
    Predicting severe toxicities with intensive induction chemotherapy for adult acute myeloid leukemia: analysis of SWOG Cancer Research Network trials S0106 and S1203.
    Leuk Lymphoma. 2021 Feb 9:1-7. doi: 10.1080/10428194.2021.1881512.

  239. PEGLIASCO J, Schmaltz-Panneau B, Martin JE, Chraibi S, et al
    ATG2B/GSKIP in de novo acute myeloid leukemia (AML): high prevalence of germline predisposition in French West Indies.
    Leuk Lymphoma. 2021 Feb 7:1-8. doi: 10.1080/10428194.2021.1881508.

  240. WAKSAL JA, Tallman MS
    Incorporation of Novel therapies for the treatment of acute myeloid leukemia: a perspective.
    Leuk Lymphoma. 2021 Feb 4:1-26. doi: 10.1080/10428194.2020.1842403.
    PubMed     Abstract available

    January 2021
  241. BENJAMIN ESB, Ravindra N, Rajamani BM, Anandan S, et al
    BCR-ABL1 kinase domain mutation analysis by next generation sequencing detected additional mutations in chronic myeloid leukemia patients with suboptimal response to imatinib.
    Leuk Lymphoma. 2021 Jan 22:1-6. doi: 10.1080/10428194.2021.1872074.

  242. WANG J, de Lima M, Cooper BW, Boughan K, et al
    Efficacy and cost-benefit of filgrastim administered after early assessment bone marrow biopsy during induction therapy for acute myeloid leukemia.
    Leuk Lymphoma. 2021 Jan 18:1-13. doi: 10.1080/10428194.2020.1864350.
    PubMed     Abstract available

  243. GARCIA-HORTON A, Maze D, McNamara CJ, Sibai H, et al
    Azacitidine and venetoclax for the treatment of accelerated and blast phase myeloproliferative neoplasms and chronic myelomonocytic leukemia: a case series.
    Leuk Lymphoma. 2021 Jan 15:1-6. doi: 10.1080/10428194.2020.1869961.

  244. LI SY, Lu Y, Liu HC, Gang EJ, et al
    Arsenic trioxide and all-trans retinoic acid in the treatment of children with newly diagnosed acute promyelocytic leukemia.
    Leuk Lymphoma. 2021 Jan 13:1-6. doi: 10.1080/10428194.2020.1856832.

  245. GHIA P, Dlugosz-Danecka M, Scarfo L, Jurczak W, et al
    Acalabrutinib: a highly selective, potent Bruton tyrosine kinase inhibitor for the treatment of chronic lymphocytic leukemia.
    Leuk Lymphoma. 2021 Jan 11:1-18. doi: 10.1080/10428194.2020.1864352.
    PubMed     Abstract available

  246. HAMPEL PJ, Parikh SA, Call TG
    Incorporating molecular biomarkers into the continuum of care in chronic lymphocytic leukemia.
    Leuk Lymphoma. 2021 Jan 7:1-22. doi: 10.1080/10428194.2020.1869966.
    PubMed     Abstract available

  247. AMMATUNA E, van Doesum J
    Acute promyelocytic leukemia: if you wait it is too late.
    Leuk Lymphoma. 2021 Jan 6:1-2. doi: 10.1080/10428194.2020.1869227.

  248. MIDDEKE JM, Teipel R, Rollig C, Stasik S, et al
    Decitabine treatment in 311 patients with acute myeloid leukemia: outcome and impact of TP53 mutations - a registry based analysis.
    Leuk Lymphoma. 2021 Jan 5:1-15. doi: 10.1080/10428194.2020.1864354.
    PubMed     Abstract available

  249. HEATLEY SL, Asari K, Schutz CE, Leclercq TM, et al
    In-vitro modeling of TKI resistance in the high-risk B-cell acute lymphoblastic leukemia fusion gene RANBP2-ABL1 - implications for targeted therapy.
    Leuk Lymphoma. 2021 Jan 2:1-13. doi: 10.1080/10428194.2020.1861275.
    PubMed     Abstract available

    December 2020
  250. ABBOTT D, Cherry E, Amaya M, McMahon C, et al
    The propriety of upgrading responses to venetoclax + azacitidine in newly diagnosed patients with acute myeloid leukemia.
    Leuk Lymphoma. 2020 Dec 30:1-9. doi: 10.1080/10428194.2020.1864358.
    PubMed     Abstract available

  251. CARBONELL D, Suarez-Gonzalez J, Chicano M, Andres-Zayas C, et al
    Genetic biomarkers identify a subgroup of high-risk patients within low-risk NPM1-mutated acute myeloid leukemia.
    Leuk Lymphoma. 2020 Dec 29:1-12. doi: 10.1080/10428194.2020.1863400.
    PubMed     Abstract available

  252. HUANG J, Pan J, Sun X, Wang R, et al
    Changes in nutritional status and serum proteins in children with acute lymphoblastic leukemia during induction therapy: a single-centre report from China.
    Leuk Lymphoma. 2020 Dec 28:1-6. doi: 10.1080/10428194.2020.1864361.

  253. HOLKOVA B, Shafer D, Yazbeck V, Dave S, et al
    Phase 1 study of belinostat (PXD-101) and bortezomib (Velcade, PS-341) in patients with relapsed or refractory acute leukemia and myelodysplastic syndrome.
    Leuk Lymphoma. 2020 Dec 28:1-14. doi: 10.1080/10428194.2020.1861270.
    PubMed     Abstract available

  254. FOLTA A, Jurcek T, Kubesova B, Zackova D, et al
    Evaluation of two CE-IVD tests for BCR-ABL1 transcript monitoring of chronic myeloid leukemia patients.
    Leuk Lymphoma. 2020 Dec 25:1-4. doi: 10.1080/10428194.2020.1861274.

  255. CHEN X, Othus M, Wood BL, Walter RB, et al
    Comparison of myeloid blast counts and variant allele frequencies of gene mutations in myelodysplastic syndrome with excess blasts and secondary acute myeloid leukemia.
    Leuk Lymphoma. 2020 Dec 19:1-7. doi: 10.1080/10428194.2020.1861267.
    PubMed     Abstract available

  256. MENDOZA H, Chen PH, Pine AB, Siddon AJ, et al
    A case of acute myeloid leukemia with unusual germline CEBPA mutation: lessons learned about mutation detection, location, and penetrance.
    Leuk Lymphoma. 2020 Dec 19:1-4. doi: 10.1080/10428194.2020.1861276.

  257. PATEL AB, Deininger MW
    Genetic complexity of chronic myelomonocytic leukemia.
    Leuk Lymphoma. 2020 Dec 18:1-22. doi: 10.1080/10428194.2020.1856837.
    PubMed     Abstract available

  258. ZHAO J, Bewersdorf JP, Jaszczur S, Kowalski A, et al
    High dose cyclophosphamide for cytoreduction in patients with acute myeloid leukemia with hyperleukocytosis or leukostasis.
    Leuk Lymphoma. 2020 Dec 16:1-13. doi: 10.1080/10428194.2020.1856835.
    PubMed     Abstract available

  259. WEIL C, Chodick G, Shalev V, Kan I, et al
    Epidemiology, longitudinal treatment patterns and outcomes of chronic lymphocytic leukemia in Israel.
    Leuk Lymphoma. 2020 Dec 11:1-14. doi: 10.1080/10428194.2020.1858293.
    PubMed     Abstract available

  260. NING L, Li D, Lu P, Que Y, et al
    Exploring the determinants that influence hospital costs of induction therapy for acute myeloid leukemia.
    Leuk Lymphoma. 2020 Dec 10:1-8. doi: 10.1080/10428194.2020.1855339.
    PubMed     Abstract available

  261. BARRIENTOS JC, Hillmen P, Salles G, Sharman J, et al
    No increased bleeding events in patients with relapsed chronic lymphocytic leukemia and indolent non-Hodgkin lymphoma treated with idelalisib.
    Leuk Lymphoma. 2020 Dec 10:1-9. doi: 10.1080/10428194.2020.1845339.
    PubMed     Abstract available

  262. CUMBO C, Orsini P, Anelli L, Zagaria A, et al
    Nanopore sequencing sheds a light on the FLT3 gene mutations complexity in acute promyelocytic leukemia.
    Leuk Lymphoma. 2020 Dec 8:1-10. doi: 10.1080/10428194.2020.1856838.
    PubMed     Abstract available

  263. TERAO T, Ashimine H, Tsuyama N, Ikeda D, et al
    Development of BCR-ABL1-positive delta T-cell leukemia after treatment for thymoma type B1.
    Leuk Lymphoma. 2020 Dec 7:1-6. doi: 10.1080/10428194.2020.1856834.

  264. ASSI R, Kantarjian H, Keating M, Pemmaraju N, et al
    Management of chronic myeloid leukemia during pregnancy among patients treated with a tyrosine kinase inhibitor: a single-Center experience.
    Leuk Lymphoma. 2020 Dec 7:1-14. doi: 10.1080/10428194.2020.1849672.
    PubMed     Abstract available

  265. CHOW EJ, Doody DR, Wilkes JJ, Becker LK, et al
    Adverse events among chronic myelogenous leukemia patients treated with tyrosine kinase inhibitors: a real-world analysis of health plan enrollees.
    Leuk Lymphoma. 2020 Dec 7:1-15. doi: 10.1080/10428194.2020.1855340.
    PubMed     Abstract available

  266. FOX TA, Carpenter B, Taj M, Perisoglou M, et al
    Utility of 18F-FDG-PET/CT in lymphoblastic lymphoma.
    Leuk Lymphoma. 2020 Dec 4:1-6. doi: 10.1080/10428194.2020.1855346.

  267. DUNN KA, Connors J, Bielawski JP, Nearing JT, et al
    Investigating the gut microbial community and genes in children with differing levels of change in serum asparaginase activity during pegaspargase treatment for acute lymphoblastic leukemia.
    Leuk Lymphoma. 2020 Dec 1:1-15. doi: 10.1080/10428194.2020.1850718.
    PubMed     Abstract available

  268. WEST ZE, Castellino SM, Monroe C, Thomas AS, et al
    Quantifying the difference in risk of adverse events by induction treatment regimen in pediatric acute lymphoblastic leukemia.
    Leuk Lymphoma. 2020 Dec 1:1-14. doi: 10.1080/10428194.2020.1852471.
    PubMed     Abstract available

  269. CHAEKAL OK, van Besien K
    Allogeneic transplant for CML in chronic phase after failure of imatinib. Not needed or needlessly neglected?
    Leuk Lymphoma. 2020;61:2783-2784.

  270. KISHTAGARI A, Sekeres MA
    Eat and be healthy: nutritional status in myelodysplastic syndromes.
    Leuk Lymphoma. 2020;61:2788-2789.

  271. SAMMARTANO V, Santoni A, Frediani B, Sicuranza A, et al
    Efficacy and safety of ruxolitinib for Covid-19 related acute respiratory distress syndrome in a patient with blastic plasmacytoid dendritic cell neoplasm (leukemic variant).
    Leuk Lymphoma. 2020;61:3523-3525.

  272. MACKENZIE S, Gill S
    Long-term outcomes in patients with AML achieving first complete remission: confronting the double-hit of survivorship.
    Leuk Lymphoma. 2020;61:3035-3037.

    November 2020
  273. SHARMAN JP, Burke JM, Yimer HA, Boxer MA, et al
    Phase 2, multicenter GIBB study of obinutuzumab plus bendamustine in previously untreated patients with chronic lymphocytic leukemia.
    Leuk Lymphoma. 2020 Nov 26:1-13. doi: 10.1080/10428194.2020.1850719.
    PubMed     Abstract available

  274. LEMIEUX-SARRASIN D, Pelland-Marcotte MC, Simonyan D, Martineau E, et al
    Distance to the pediatric oncology center does not affect survival in children with acute lymphoblastic leukemia: a report from CYP-C.
    Leuk Lymphoma. 2020 Nov 24:1-11. doi: 10.1080/10428194.2020.1849673.
    PubMed     Abstract available

  275. RASOR B, Dickerson T, Zhao Q, Elder P, et al
    Comparison of fixed dose reduced-intensity conditioning with fludarabine and busulfan to PK-guided busulfan AUC (FluBu4K) in hematopoietic stem cell transplant for AML/MDS.
    Leuk Lymphoma. 2020 Nov 24:1-10. doi: 10.1080/10428194.2020.1849677.
    PubMed     Abstract available

  276. GREEN K, Tandon S, Ahmed M, Toscano W, et al
    Congenital acute myeloid leukemia: challenges and lessons. A 15-year experience from the UK.
    Leuk Lymphoma. 2020 Nov 23:1-8. doi: 10.1080/10428194.2020.1845335.
    PubMed     Abstract available

  277. WANG Z, Guan W, Wang M, Chen J, et al
    AML1-ETO inhibits acute myeloid leukemia immune escape by CD48.
    Leuk Lymphoma. 2020 Nov 21:1-10. doi: 10.1080/10428194.2020.1849680.
    PubMed     Abstract available

  278. KHOUNTHAM S, Shindiapina P, Mo X, Lachowiez C, et al
    Natural history of noninfectious, ibrutinib-attributable adverse events in patients with chronic lymphocytic leukemia.
    Leuk Lymphoma. 2020 Nov 19:1-6. doi: 10.1080/10428194.2020.1838508.

  279. WANG T, Zhou B, Zhang J, Zhang X, et al
    Allogeneic hematopoietic stem cell transplantation could improve survival for pure CBF-AML patients with minimal residual disease positive after the second consolidation.
    Leuk Lymphoma. 2020 Nov 16:1-4. doi: 10.1080/10428194.2020.1846736.
    PubMed     Abstract available

  280. FU W, Huang A, Lu G, Ni X, et al
    Value of pre-transplant consolidation chemotherapy in adults with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation without minimal residual disease in first complete remission.
    Leuk Lymphoma. 2020 Nov 11:1-8. doi: 10.1080/10428194.2020.1845340.
    PubMed     Abstract available

  281. MESSORI A, Bartoli L
    Restricted mean survival time in patients with chronic lymphocytic leukemia treated with chemotherapy-free regimens as first line.
    Leuk Lymphoma. 2020 Nov 9:1. doi: 10.1080/10428194.2020.1845337.

  282. COUTURIER MA, Thomas X, Raffoux E, Huguet F, et al
    Blinatumomab + ponatinib for relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia in adults.
    Leuk Lymphoma. 2020 Nov 6:1-10. doi: 10.1080/10428194.2020.1844198.
    PubMed     Abstract available

  283. OTTMANN OG, Stegelmann F, Breccia M, Steegmann JL, et al
    Smoothened inhibitor erismodegib combined with nilotinib in patients with chronic myeloid leukemia resistant/intolerant to at least one prior tyrosine kinase inhibitor: a phase 1b study.
    Leuk Lymphoma. 2020 Nov 6:1-4. doi: 10.1080/10428194.2020.1839649.

  284. EFFICACE F, Iurlo A, Patriarca A, Stagno F, et al
    Validation and reference values of the EORTC QLQ-CML24 questionnaire to assess health-related quality of life in patients with chronic myeloid leukemia.
    Leuk Lymphoma. 2020 Nov 6:1-10. doi: 10.1080/10428194.2020.1838509.
    PubMed     Abstract available

  285. TROMP VNMF, Timmers L, Koningen L, Janssen JJWM, et al
    Tyrosine kinase inhibitor treatment discontinuation in chronic myeloid leukemia: patient views.
    Leuk Lymphoma. 2020 Nov 6:1-10. doi: 10.1080/10428194.2020.1839655.
    PubMed     Abstract available

  286. LUNGHI M, Patriarca A, Greco M, Taherinasab A, et al
    Ponatinib for the treatment of Ph-like acute lymphoblastic leukemia.
    Leuk Lymphoma. 2020 Nov 5:1-3. doi: 10.1080/10428194.2020.1842401.

  287. SHI D, Li Z, Li Y, Jiang Q, et al
    Variables associated with self-reported anxiety and depression symptoms in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitor therapy.
    Leuk Lymphoma. 2020 Nov 5:1-9. doi: 10.1080/10428194.2020.1842397.
    PubMed     Abstract available

  288. BUSCHNER G, Feuerecker B, Spinner S, Seidl C, et al
    Differentiation of acute myeloid leukemia (AML) cells with ATRA reduces (18)F-FDG uptake and increases sensitivity towards ABT-737-induced apoptosis.
    Leuk Lymphoma. 2020 Nov 3:1-10. doi: 10.1080/10428194.2020.1839648.
    PubMed     Abstract available

  289. GAUT D, Mead M
    Measurable residual disease in hematopoietic stem cell transplantation-eligible patients with acute myeloid leukemia: clinical significance and promising therapeutic strategies.
    Leuk Lymphoma. 2020 Nov 2:1-24. doi: 10.1080/10428194.2020.1827251.
    PubMed     Abstract available

  290. MEGIAS-VERICAT JE, Martinez-Cuadron D, Herrero MJ, Rodriguez-Veiga R, et al
    Impact of combinations of single-nucleotide polymorphisms of anthracycline transporter genes upon the efficacy and toxicity of induction chemotherapy in acute myeloid leukemia.
    Leuk Lymphoma. 2020 Nov 2:1-10. doi: 10.1080/10428194.2020.1839650.
    PubMed     Abstract available

    Toward a cure in relapsed ALL: we must do better.
    Leuk Lymphoma. 2020;61:2544-2545.

  292. PAN W, Zhao X, Shi W, Jiang Z, et al
    Venetoclax induced complete remission in extramedullary relapse of AML co-harboring NPM1, TET2, and NRAS mutations after haploidentical hematopoietic stem cell transplantation.
    Leuk Lymphoma. 2020;61:2756-2759.

    October 2020
    Improving end-of-life care for patients with leukemia: is inpatient death the right measure?
    Leuk Lymphoma. 2020 Oct 29:1-3. doi: 10.1080/10428194.2020.1838510.

  294. VAKRMANOVA B, Fronkova E, Zuna J, Janotova I, et al
    Blast clearance after one week of corticosteroids correlates with outcome and genetics but does not justify adding a residual disease time point in acute lymphoblastic leukemia treatment.
    Leuk Lymphoma. 2020 Oct 29:1-3. doi: 10.1080/10428194.2020.1839659.

  295. BARSOUM B, Henneman A, Ahmad S, Ghiuzeli C, et al
    Evaluation of the efficacy and safety of arsenic trioxide dosing in obese patients with acute promyelocytic leukemia.
    Leuk Lymphoma. 2020 Oct 27:1-6. doi: 10.1080/10428194.2020.1837797.
    PubMed     Abstract available

  296. KARIGANE D, Kasahara H, Shiroshita K, Fujita S, et al
    Detection of residual disease in chronic myeloid leukemia utilizing genomic next generation sequencing reveals persistence of differentiated Ph(+) B cells but not bone marrow stem/progenitors.
    Leuk Lymphoma. 2020 Oct 26:1-9. doi: 10.1080/10428194.2020.1837366.
    PubMed     Abstract available

  297. FREYER CW, Peterson CE, Man Y, Przespolewski A, et al
    Herpes zoster during arsenic trioxide therapy for acute promyelocytic leukemia.
    Leuk Lymphoma. 2020 Oct 26:1-7. doi: 10.1080/10428194.2020.1838507.
    PubMed     Abstract available

  298. RODGERS TD, Williams AM, Baran A, Reagan PM, et al
    Toxicity patterns of novel PI3K combinations in patients with non-Hodgkin lymphoma.
    Leuk Lymphoma. 2020 Oct 25:1-8. doi: 10.1080/10428194.2020.1837796.
    PubMed     Abstract available

  299. PETERLIN P, Chevallier P, Knapper S, Collin M, et al
    FLT3 ligand in acute myeloid leukemia: a simple test with deep implications.
    Leuk Lymphoma. 2020 Oct 20:1-7. doi: 10.1080/10428194.2020.1834091.
    PubMed     Abstract available

  300. NORRIS EJ, Patel YC, Klotz KE, Steuerwald N, et al
    Dexrazoxane enhances efficacy of all-trans retinoic acid in acute myeloid leukemia patient blast cells and cell lines.
    Leuk Lymphoma. 2020 Oct 16:1-5. doi: 10.1080/10428194.2020.1827245.

  301. LU J, Wu X, Wang L, Li T, et al
    Long noncoding RNA LINC00467 facilitates the progression of acute myeloid leukemia by targeting the miR-339/SKI pathway.
    Leuk Lymphoma. 2020 Oct 15:1-10. doi: 10.1080/10428194.2020.1832667.
    PubMed     Abstract available

  302. CUI L, Gao C, Wang CJ, Zhao XX, et al
    Combined analysis of IKZF1 deletions and CRLF2 expression on prognostic impact in pediatric B-cell precursor acute lymphoblastic leukemia.
    Leuk Lymphoma. 2020 Oct 15:1-9. doi: 10.1080/10428194.2020.1832668.
    PubMed     Abstract available

  303. O'BRIEN G, Zyla J, Manola KN, Pagoni MN, et al
    Identification of two novel mutations in human acute myeloid leukemia cases.
    Leuk Lymphoma. 2020 Oct 14:1-8. doi: 10.1080/10428194.2020.1832664.
    PubMed     Abstract available

  304. LOH JBE, Walker P, Avery S, Patil S, et al
    Double trouble or a silver lining? A case report of two patients with NPM1-mutated donor-derived acute myeloid leukemia (AML).
    Leuk Lymphoma. 2020 Oct 13:1-3. doi: 10.1080/10428194.2020.1832663.

  305. WILLEKENS C, Rahme R, Duchmann M, Vidal V, et al
    Effects of azacitidine in 93 patients with IDH1/2 mutated acute myeloid leukemia/myelodysplastic syndromes: a French retrospective multicenter study.
    Leuk Lymphoma. 2020 Oct 12:1-8. doi: 10.1080/10428194.2020.1832661.
    PubMed     Abstract available

  306. LOH KP, Abdallah M, Kadambi S, Wells M, et al
    Treatment decision-making in acute myeloid leukemia: a qualitative study of older adults and community oncologists.
    Leuk Lymphoma. 2020 Oct 11:1-12. doi: 10.1080/10428194.2020.1832662.
    PubMed     Abstract available

  307. HEINICKE T, Labopin M, Polge E, Stelljes M, et al
    Evaluation of six different types of sequential conditioning regimens for allogeneic stem cell transplantation in relapsed/refractory acute myelogenous leukemia - a study of the Acute Leukemia Working Party of the EBMT.
    Leuk Lymphoma. 2020 Oct 11:1-11. doi: 10.1080/10428194.2020.1827248.
    PubMed     Abstract available

  308. ZACKOVA D, Klamova H, Belohlavkova P, Stejskal L, et al
    Dasatinib treatment long-term results among imatinib-resistant/intolerant patients with chronic phase chronic myeloid leukemia are favorable in daily clinical practice.
    Leuk Lymphoma. 2020 Oct 6:1-9. doi: 10.1080/10428194.2020.1827242.
    PubMed     Abstract available

  309. ANDERSON MA, Seymour JF
    Tumor lysis syndrome: still the Achilles heel of venetoclax in treatment of CLL?
    Leuk Lymphoma. 2020;61:2286-2288.

  310. REYNOLDS G, Slavin M, Teh BW
    Ibrutinib and invasive fungal infections: the known, the unknown and the known unknowns.
    Leuk Lymphoma. 2020;61:2292-2294.

    September 2020
  311. SILVEIRA DRA, Coelho-Silva JL, Silva WF, Vallance G, et al
    A multicenter comparative acute myeloid leukemia study: can we explain the differences in the outcomes in resource-constrained settings?
    Leuk Lymphoma. 2020 Sep 30:1-11. doi: 10.1080/10428194.2020.1827252.
    PubMed     Abstract available

  312. ZHOU D, Xu P, Zhou X, Diao Z, et al
    MiR-181a enhances drug sensitivity of mixed lineage leukemia-rearranged acute myeloid leukemia by increasing poly(ADP-ribose) polymerase1 acetylation.
    Leuk Lymphoma. 2020 Sep 30:1-11. doi: 10.1080/10428194.2020.1824067.
    PubMed     Abstract available

  313. XIE J, Nachabe A, Hathaway LJ, Farah B, et al
    The prognostic implications of tetraploidy/near-Tetraploidy in acute myeloid leukemia: a case series and systematic review of the literature.
    Leuk Lymphoma. 2020 Sep 29:1-8. doi: 10.1080/10428194.2020.1817435.
    PubMed     Abstract available

  314. DALEY RJ, Rajeeve S, Kabel CC, Pappacena JJ, et al
    Tolerability and toxicity of pegaspargase in adults 40 years and older with acute lymphoblastic leukemia.
    Leuk Lymphoma. 2020 Sep 26:1-9. doi: 10.1080/10428194.2020.1824068.
    PubMed     Abstract available

  315. CORTES JE, Candoni A, Clark RE, Leber B, et al
    Selection and management of older patients with acute myeloid leukemia treated with glasdegib plus low-dose cytarabine: expert panel review.
    Leuk Lymphoma. 2020 Sep 24:1-19. doi: 10.1080/10428194.2020.1817445.
    PubMed     Abstract available

  316. SHAH N, Rockwell B, Kazemi M, Peeke S, et al
    Ethnic disparities in survival of adult B-cell acute lymphoblastic leukemia in modern era - a SEER analysis.
    Leuk Lymphoma. 2020 Sep 22:1-4. doi: 10.1080/10428194.2020.1808211.

  317. YILMAZ M, Kantarjian HM, Toruner G, Yin CC, et al
    Translocation t(1;19)(q23;p13) in adult acute lymphoblastic leukemia - a distinct subtype with favorable prognosis.
    Leuk Lymphoma. 2020 Sep 21:1-5. doi: 10.1080/10428194.2020.1824071.
    PubMed     Abstract available

  318. MUSHTAQ MU, Harrington AM, Chaudhary SG, Michaelis LC, et al
    Comparison of salvage chemotherapy regimens and prognostic significance of minimal residual disease in relapsed/refractory acute myeloid leukemia.
    Leuk Lymphoma. 2020 Sep 19:1-9. doi: 10.1080/10428194.2020.1821009.
    PubMed     Abstract available

  319. HALPERN AB, Othus M, Howard NP, Hendrie PC, et al
    Comparison of outpatient care following intensive induction versus post-remission chemotherapy for adults with acute myeloid leukemia and other high-grade myeloid neoplasms.
    Leuk Lymphoma. 2020 Sep 13:1-5. doi: 10.1080/10428194.2020.1821008.

  320. AVGERINOU G, Katsibardi Kappa, Filippidou M, Tzanoudaki M, et al
    Cytogenetically cryptic and fish negative PML/RARA rearrangement in acute promyelocytic leukemia detected by RT-PCR.
    Leuk Lymphoma. 2020 Sep 10:1-3. doi: 10.1080/10428194.2020.1808202.

  321. DAO FT, Chen WM, Long LY, Li LD, et al
    High PRDM16 expression predicts poor outcomes in adult acute myeloid leukemia patients with intermediate cytogenetic risk: a comprehensive cohort study from a single Chinese center.
    Leuk Lymphoma. 2020 Sep 9:1-9. doi: 10.1080/10428194.2020.1817436.
    PubMed     Abstract available

    Immune impacts of Bruton tyrosine kinase inhibitors in chronic lymphocytic leukemia patients: are we closer to a holy grail?
    Leuk Lymphoma. 2020 Sep 8:1-3. doi: 10.1080/10428194.2020.1811865.

  323. YOST CM, Gaikwad AS, Parsons DW, Rabin KR, et al
    Aberrant leukemia-associated immunophenotype as potential harbinger of lineage switch in KMT2A-rearranged leukemia: a case series.
    Leuk Lymphoma. 2020 Sep 2:1-4. doi: 10.1080/10428194.2020.1815018.

    August 2020
  324. MOHAMMAD IS, Lin K, Oates M, Khan UT, et al
    Development of a cell-line model to mimic the pro-survival effect of nurse-like cells in chronic lymphocytic leukemia.
    Leuk Lymphoma. 2020 Aug 28:1-13. doi: 10.1080/10428194.2020.1811274.
    PubMed     Abstract available

  325. ZHOU X, Ma X, Sun H, Li X, et al
    Let-7b regulates the adriamycin resistance of chronic myelogenous leukemia by targeting AURKB in K562/ADM cells.
    Leuk Lymphoma. 2020 Aug 28:1-9. doi: 10.1080/10428194.2020.1811269.
    PubMed     Abstract available

  326. ARUNACHALAM AK, Janet NB, Korula A, Lakshmi KM, et al
    Prognostic value of MRD monitoring based on BCR-ABL1 copy numbers in Philadelphia chromosome positive acute lymphoblastic leukemia.
    Leuk Lymphoma. 2020 Aug 27:1-8. doi: 10.1080/10428194.2020.1811272.
    PubMed     Abstract available

  327. SINGH A, Motilal Nehru V, Peace D
    Refractory acquired angioedema in chronic lymphocytic leukemia.
    Leuk Lymphoma. 2020 Aug 25:1-2. doi: 10.1080/10428194.2020.1804559.

  328. ROBERTS KE, Deininger MW, Hildebrandt GC, Gackenbach BK, et al
    Use of dasatinib dose-reduction periods to remedy poor surgical wound healing in Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Leuk Lymphoma. 2020 Aug 24:1-4. doi: 10.1080/10428194.2020.1808210.

  329. ROBOZ GJ, Strickland SA, Litzow MR, Dalovisio A, et al
    Updated safety of midostaurin plus chemotherapy in newly diagnosed FLT3 mutation-positive acute myeloid leukemia: the RADIUS-X expanded access program.
    Leuk Lymphoma. 2020 Aug 19:1-8. doi: 10.1080/10428194.2020.1805109.
    PubMed     Abstract available

  330. NAGAHATA Y, Kondo T, Ono Y, Hiramoto N, et al
    High-dose cytarabine chemotherapy (>/=4 g/m(2)/day) before allogeneic hematopoietic stem cell transplantation for non-core-binding-factor AML in the first complete remission.
    Leuk Lymphoma. 2020 Aug 17:1-9. doi: 10.1080/10428194.2020.1805112.
    PubMed     Abstract available

  331. SCALZULLI E, Colafigli G, Pepe S, De Luca G, et al
    Real-life evaluation of potential candidates for treatment discontinuation in chronic myeloid leukemia: the impact of age and long-term follow-up.
    Leuk Lymphoma. 2020 Aug 16:1-2. doi: 10.1080/10428194.2020.1808205.

  332. TRANG E, Ngo D, Chen J, Aldoss I, et al
    Levocarnitine for pegasparaginase-induced hepatotoxicity in acute lymphoblastic leukemia.
    Leuk Lymphoma. 2020 Aug 13:1-4. doi: 10.1080/10428194.2020.1805108.
    PubMed     Abstract available

  333. LIU X, Zou Y, Chen X, Wang S, et al
    Minimal residual disease surveillance at day 90 predicts long-term survival in pediatric patients with T-cell acute lymphoblastic leukemia.
    Leuk Lymphoma. 2020 Aug 11:1-8. doi: 10.1080/10428194.2020.1805739.
    PubMed     Abstract available

  334. ANDREWS C, Lam W, Sibai H
    The successful use of FLT3 inhibitors in FLT3-positive mixed phenotype acute leukemia.
    Leuk Lymphoma. 2020 Aug 6:1-3. doi: 10.1080/10428194.2020.1802451.

  335. FRASER GAM, Chanan-Khan A, Demirkan F, Santucci Silva R, et al
    Final 5-year findings from the phase 3 HELIOS study of ibrutinib plus bendamustine and rituximab in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma.
    Leuk Lymphoma. 2020 Aug 6:1-10. doi: 10.1080/10428194.2020.1795159.
    PubMed     Abstract available

  336. SHAIKH AF, Kakirde C, Dhamne C, Bhanshe P, et al
    Machine learning derived genomics driven prognostication for acute myeloid leukemia with RUNX1-RUNX1T1.
    Leuk Lymphoma. 2020 Aug 5:1-7. doi: 10.1080/10428194.2020.1798951.
    PubMed     Abstract available

  337. MAJOR CK, Kantarjian H, Sasaki K, Borthakur G, et al
    Survivorship in AML - a landmark analysis on the outcomes of acute myelogenous leukemia patients after maintaining complete remission for at least 3 years.
    Leuk Lymphoma. 2020 Aug 5:1-8. doi: 10.1080/10428194.2020.1802450.
    PubMed     Abstract available

  338. OBIORAH IE, Francischetti IMB, Wang HW, Ahn IE, et al
    Concurrent chronic lymphocytic leukemia/small lymphocytic lymphoma and hairy cell leukemia: clinical, pathologic and molecular features.
    Leuk Lymphoma. 2020 Aug 5:1-11. doi: 10.1080/10428194.2020.1797007.
    PubMed     Abstract available

    July 2020
  339. JANN JC, Streuer A, Hecht A, Nolte F, et al
    RNA-sequencing of acute promyelocytic leukemia primary blasts reveals novel molecular biomarkers of early death events.
    Leuk Lymphoma. 2020 Jul 29:1-12. doi: 10.1080/10428194.2020.1797006.
    PubMed     Abstract available

  340. MENDES-DE-ALMEIDA DP, Sellos F, Moura PG, Dos Santos-Bueno FV, et al
    Acute myeloid leukemia associated with a novel GATA2 mutation: a case report and the importance to identify GATA2 haplodeficiency.
    Leuk Lymphoma. 2020 Jul 27:1-4. doi: 10.1080/10428194.2020.1795163.

  341. SCHULZ WL, Rinder HM, Durant TJS, Tormey CA, et al
    Impact of intra-tumoral heterogeneity detected by next-generation sequencing on acute myeloid leukemia survival.
    Leuk Lymphoma. 2020 Jul 26:1-3. doi: 10.1080/10428194.2020.1797016.

  342. VALLATHOL DH, Ali AZ, Alapati N, Manasa N, et al
    Lutetium 177 dotatate induced acute myeloid leukemia.
    Leuk Lymphoma. 2020 Jul 25:1-3. doi: 10.1080/10428194.2020.1795158.

  343. CHEN Z, Hu S, Wang SA, Konopleva M, et al
    Chronic myeloid leukemia presenting in lymphoblastic crisis, a differential diagnosis with Philadelphia-positive B-lymphoblastic leukemia.
    Leuk Lymphoma. 2020 Jul 23:1-8. doi: 10.1080/10428194.2020.1795160.
    PubMed     Abstract available

  344. THAKRAL B, Daver N, Tang Z, Patel KP, et al
    Clonal evolution with acquisition of BCR-ABL1 in refractory acute myeloid leukemia post therapy with FLT3-inhibitor.
    Leuk Lymphoma. 2020 Jul 22:1-4. doi: 10.1080/10428194.2020.1797008.

  345. BARTHEL R, Fedorchenko O, Velmans T, Rosen N, et al
    CD74 is dispensable for development of chronic lymphocytic leukemia in Emicro-TCL1 transgenic mice.
    Leuk Lymphoma. 2020 Jul 15:1-12. doi: 10.1080/10428194.2020.1791851.
    PubMed     Abstract available

  346. HU B, Lin X, Lee HC, Huang X, et al
    Timing of allogeneic hematopoietic cell transplantation (alloHCT) for chronic myeloid leukemia (CML) patients.
    Leuk Lymphoma. 2020 Jul 14:1-10. doi: 10.1080/10428194.2020.1783444.
    PubMed     Abstract available

  347. Detection and clinical significance of gene rearrangements in Chinese patients with adult acute lymphoblastic leukemia.
    Leuk Lymphoma. 2020 Jul 14:1. doi: 10.1080/10428194.2020.1794540.

  348. NESR G, Laffan M, Claudiani S, Innes A, et al
    Platelet function in patients with chronic myeloid leukemia treated with asciminib.
    Leuk Lymphoma. 2020 Jul 12:1-3. doi: 10.1080/10428194.2020.1791856.

  349. ALOTAIBI AS, Abdulrazzaq M, Patel KP, Ravandi F, et al
    Acute promyelocytic leukemia (APL) with an IRF2BP2-RARA fusion transcript: an aggressive APL variant.
    Leuk Lymphoma. 2020 Jul 11:1-3. doi: 10.1080/10428194.2020.1791853.

  350. SAKURAI A, Nakazato T
    The prognostic value of the controlling nutritional status score in patients with myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia related changes treated with azacitidine.
    Leuk Lymphoma. 2020 Jul 11:1-3. doi: 10.1080/10428194.2020.1791847.

  351. PANDEY RK, DiPippo A, Kadia T, Pemmaraju N, et al
    Nelarabine-related rhabdomyolysis in a patient with T-cell acute lymphoblastic leukemia.
    Leuk Lymphoma. 2020 Jul 11:1-3. doi: 10.1080/10428194.2020.1791852.

  352. ZHAO X, Lu X, Tang L, Yan H, et al
    Comparing the outcomes between TMLI and non-TMLI conditioning regimens for adult high-risk acute lymphoblastic leukemia patients undergoing allogeneic hematopoietic stem cell transplantation: a single-center experience.
    Leuk Lymphoma. 2020 Jul 10:1-9. doi: 10.1080/10428194.2020.1789621.
    PubMed     Abstract available

  353. ALI N, Tomlinson B, Metheny L, Goldstein SC, et al
    Conditioning regimen intensity and low-dose azacitidine maintenance after allogeneic hematopoietic cell transplantation for acute myeloid leukemia.
    Leuk Lymphoma. 2020 Jul 10:1-11. doi: 10.1080/10428194.2020.1789630.
    PubMed     Abstract available

  354. LIU K, Chu J, Dai Y, Jiang A, et al
    Long-term follow-up of acute lymphoblastic leukemia in young children treated by the SCMC-ALL-2009 protocol.
    Leuk Lymphoma. 2020 Jul 9:1-9. doi: 10.1080/10428194.2020.1786557.
    PubMed     Abstract available

  355. GODWIN CD, Bates OM, Jean SR, Laszlo GS, et al
    Anti-apoptotic BCL-2 family proteins confer resistance to calicheamicin-based antibody-drug conjugate therapy of acute leukemia.
    Leuk Lymphoma. 2020 Jul 4:1-5. doi: 10.1080/10428194.2020.1786553.

  356. GOKBUGET N, Zugmaier G, Dombret H, Stein A, et al
    Curative outcomes following blinatumomab in adults with minimal residual disease B-cell precursor acute lymphoblastic leukemia.
    Leuk Lymphoma. 2020 Jul 3:1-9. doi: 10.1080/10428194.2020.1780583.
    PubMed     Abstract available

  357. DE CASTRO CG JR, Gregianin LJ, Burger JA
    Continuous high-dose ivermectin appears to be safe in patients with acute myelogenous leukemia and could inform clinical repurposing for COVID-19 infection.
    Leuk Lymphoma. 2020 Jul 1:1-2. doi: 10.1080/10428194.2020.1786559.

  358. MULLIKIN D, Ranch D, Khalfe Y, Lucari B, et al
    Hispanic ethnicity is associated with prolonged clearance of high dose methotrexate and severe nephrotoxicity in children and adolescents with acute lymphoblastic leukemia.
    Leuk Lymphoma. 2020 Jul 1:1-4. doi: 10.1080/10428194.2020.1783445.

  359. ZHANG Z, Zhang R, Qi J, Miao W, et al
    The prognostic value of plasma fibrinogen level in patients with acute myeloid leukemia: a systematic review and meta-analysis.
    Leuk Lymphoma. 2020 Jul 1:1-10. doi: 10.1080/10428194.2020.1780587.
    PubMed     Abstract available

  360. HSU J, Van Besien K, Baron F
    Busulfan or melphalan: is there a better conditioning regimen for allogeneneic transplantation?
    Leuk Lymphoma. 2020;61:1529-1534.

    June 2020
  361. SHIMONY S, Rozovski U, Sudry N, Yeshurun M, et al
    Early detection of infectious complications during induction therapy for acute leukemia with serial C-reactive protein biomarker assessment.
    Leuk Lymphoma. 2020 Jun 24:1-6. doi: 10.1080/10428194.2020.1779253.
    PubMed     Abstract available

  362. COTE-OLIJNYK M, Fowlkes S, Assouline S
    Chronic myelogenous leukemia presenting as central retinal vein occlusion.
    Leuk Lymphoma. 2020 Jun 22:1-4. doi: 10.1080/10428194.2020.1775203.

  363. SHOAG JM, Barredo JC, Lossos IS, Pinheiro PS, et al
    Acute lymphoblastic leukemia mortality in Hispanic Americans.
    Leuk Lymphoma. 2020 Jun 22:1-8. doi: 10.1080/10428194.2020.1779260.
    PubMed     Abstract available

  364. MOHYUDDIN GR, Abbasi S, Ripp J, Singh A, et al
    Patients with leukemia dying in the hospital: results of the national inpatient sample and a call to do better.
    Leuk Lymphoma. 2020 Jun 18:1-3. doi: 10.1080/10428194.2020.1780585.

  365. MOLICA S, Lentini M, Zappala D, Levato L, et al
    Effects of ibrutinib on glucose-lipid metabolism in patients with chronic lymphocytic leukemia (CLL).
    Leuk Lymphoma. 2020 Jun 16:1-3. doi: 10.1080/10428194.2020.1779258.

  366. LU JP, Wang FX, Wen SP, Liu X, et al
    Haploidentical hematopoietic stem cell transplantation with 'Beijing protocol' in the treatment of T-lymphoblastic lymphoma.
    Leuk Lymphoma. 2020 Jun 16:1-4. doi: 10.1080/10428194.2020.1775205.

  367. LI AY, Kashanian SM, Hambley BC, Zacholski K, et al
    Clustered incidence of adult acute promyelocytic leukemia in the vicinity of Baltimore.
    Leuk Lymphoma. 2020 Jun 14:1-5. doi: 10.1080/10428194.2020.1775209.

  368. RASHED RA, Hassan NM, Hussein MM
    MicroRNA-92a as a marker of treatment response and survival in adult acute myeloid leukemia patients.
    Leuk Lymphoma. 2020 Jun 14:1-7. doi: 10.1080/10428194.2020.1775218.
    PubMed     Abstract available

  369. FREI M, Aitken SL, Jain N, Thompson P, et al
    Incidence and characterization of fungal infections in chronic lymphocytic leukemia patients receiving ibrutinib.
    Leuk Lymphoma. 2020 Jun 12:1-4. doi: 10.1080/10428194.2020.1775215.

  370. TAVITIAN S, Uzunov M, Berard E, Bouscary D, et al
    Ponatinib-based therapy in adults with relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia: results of the real-life OPAL study.
    Leuk Lymphoma. 2020 Jun 8:1-7. doi: 10.1080/10428194.2020.1762876.
    PubMed     Abstract available

  371. PAGANI IS, Dang P, Saunders VA, Braley J, et al
    Clinical utility of genomic DNA Q-PCR for the monitoring of a patient with atypical e19a2 BCR-ABL1 transcripts in chronic myeloid leukemia.
    Leuk Lymphoma. 2020 Jun 6:1-3. doi: 10.1080/10428194.2020.1772476.

  372. PLEYER C, Sun C, Desai S, Ahn IE, et al
    Reconstitution of humoral immunity and decreased risk of infections in patients with chronic lymphocytic leukemia treated with Bruton tyrosine kinase inhibitors.
    Leuk Lymphoma. 2020 Jun 6:1-8. doi: 10.1080/10428194.2020.1772477.
    PubMed     Abstract available

  373. CHEN QC, Chen YH
    Mutational profiling of myeloid neoplasms, focusing on AML with myelodysplasia-related changes (MRC) in comparison with MDS and AML without MRC.
    Leuk Lymphoma. 2020;61:1269-1271.

  374. TADMOR T, Greenfeld S
    Incidence and diagnosis of Richter transformation: transition from the era of chemoimmunotherapy to novel targeted agents.
    Leuk Lymphoma. 2020;61:1272-1274.

  375. MATUTES E, Polliack A
    The challenge of unavailable IGH mutational status in CLL in resource-limited settings.
    Leuk Lymphoma. 2020;61:1275-1276.

    May 2020
  376. STRICKLAND SA, Wang XV, Cerny J, Rowe JM, et al
    A novel PrECOG (PrE0901) dose-escalation trial using eltrombopag: enhanced platelet recovery during consolidation therapy in acute myeloid leukemia.
    Leuk Lymphoma. 2020 May 30:1-9. doi: 10.1080/10428194.2020.1762878.
    PubMed     Abstract available

  377. NIE L, Ma R, Yuan X, Jiang L, et al
    The prognostic value of CD2, CD4, and HLA-DR expression and FLT3-ITD mutation in adult acute promyelocytic leukemia.
    Leuk Lymphoma. 2020 May 30:1-6. doi: 10.1080/10428194.2020.1768386.
    PubMed     Abstract available

  378. COHEN J, Palumbo A, Wing J, Heinrich MC, et al
    Case series of chronic myeloid leukemia patients who maintained deep molecular response (DMR) with very low-dose ponatinib: experience in discontinuing low-dose ponatinib and treatment-free remission (TFR) outcomes.
    Leuk Lymphoma. 2020 May 26:1-4. doi: 10.1080/10428194.2020.1768380.

  379. KOEHLER AB, Leung N, Call TG, Rabe KG, et al
    Incidence and risk of tumor lysis syndrome in patients with relapsed chronic lymphocytic leukemia (CLL) treated with venetoclax in routine clinical practice.
    Leuk Lymphoma. 2020 May 25:1-6. doi: 10.1080/10428194.2020.1768384.
    PubMed     Abstract available

  380. BRUZZESE A, Chistolini A, Morano SG, Fegatelli DA, et al
    Peripherally inserted central catheter in patients with acute myeloid leukemia: incidence and risk factors for premature removal.
    Leuk Lymphoma. 2020 May 21:1-3. doi: 10.1080/10428194.2020.1762880.

  381. WANG ES, Aplenc R, Chirnomas D, Dugan M, et al
    Safety of gemtuzumab ozogamicin as monotherapy or combination therapy in an expanded-access protocol for patients with relapsed or refractory acute myeloid leukemia.
    Leuk Lymphoma. 2020 May 20:1-9. doi: 10.1080/10428194.2020.1742897.
    PubMed     Abstract available

  382. KNEZ V, Bao L, Carstens B, Liang X, et al
    Analysis of clinicopathological and cytogenetic differences between B-lymphoblastic lymphoma and B-lymphoblastic leukemia in childhood.
    Leuk Lymphoma. 2020 May 19:1-7. doi: 10.1080/10428194.2020.1761970.
    PubMed     Abstract available

  383. FULCHER J, Leung E, Christou G, Bredeson C, et al
    Selecting the optimal targeted therapy for relapsed B-acute lymphoblastic leukemia.
    Leuk Lymphoma. 2020 May 19:1-3. doi: 10.1080/10428194.2020.1761965.

  384. PETTERSSON L, Chen Y, George AM, Rigo R, et al
    Subclonal patterns in follow-up of acute myeloid leukemia combining whole exome sequencing and ultrasensitive IBSAFE digital droplet analysis.
    Leuk Lymphoma. 2020 May 19:1-12. doi: 10.1080/10428194.2020.1755855.
    PubMed     Abstract available

  385. BEWERSDORF JP, Zeidan AM
    Following in the footsteps of acute myeloid leukemia: are we witnessing the start of a therapeutic revolution for higher-risk myelodysplastic syndromes?
    Leuk Lymphoma. 2020 May 18:1-18. doi: 10.1080/10428194.2020.1761968.
    PubMed     Abstract available

  386. GAULIN C, Chan A, Derkach A, Park JH, et al
    Hypofibrinogenemia and disseminated intravascular coagulation rarely complicate treatment-naive acute lymphoblastic leukemia.
    Leuk Lymphoma. 2020 May 18:1-5. doi: 10.1080/10428194.2020.1765236.

  387. PAPANOTA AM, Ntanasis-Stathopoulos I, Liakea A, Kastritis E, et al
    Primary plasma cell leukemia presenting as secondary pulmonary alveolar proteinosis.
    Leuk Lymphoma. 2020 May 13:1-4. doi: 10.1080/10428194.2020.1761969.

  388. JABBOUR E, Stelljes M, Advani AS, DeAngelo DJ, et al
    Impact of salvage treatment phase on inotuzumab ozogamicin treatment for relapsed/refractory acute lymphoblastic leukemia: an update from the INO-VATE final study database.
    Leuk Lymphoma. 2020 May 7:1-4. doi: 10.1080/10428194.2020.1751839.

  389. HAN H, Shin DY, Kim D, Kim H, et al
    Induction of leukemic stem cell differentiation by aryl hydrocarbon receptor agonist and synergy with gilteritinib in FLT3-ITD + acute myeloid leukemia.
    Leuk Lymphoma. 2020 May 6:1-11. doi: 10.1080/10428194.2020.1747062.
    PubMed     Abstract available

  390. LUSKIN MR, Kim AS, Patel SS, Wright K, et al
    Evidence for separate transformation to acute myeloid leukemia and blastic plamacytoid dendritic cell neoplasm from a shared ancestral hematopoietic clone.
    Leuk Lymphoma. 2020 May 4:1-4. doi: 10.1080/10428194.2020.1755856.

  391. TODISCO E, Gigli F, Sammassimo S, Camisaschi C, et al
    Efficacy of venetoclax based salvage chemotherapy followed by "Minimal Residual Disease driven"-venetoclax maintenance therapy post-allotransplant in a young patient with high risk primary refractory acute myeloid leukemia.
    Leuk Lymphoma. 2020 May 2:1-3. doi: 10.1080/10428194.2020.1759049.

  392. BEWERSDORF JP, Shallis RM, Gowda L, Wei W, et al
    Clinical outcomes and characteristics of patients with TP53-mutated acute myeloid leukemia or myelodysplastic syndromes: a single center experience.
    Leuk Lymphoma. 2020 May 2:1-11. doi: 10.1080/10428194.2020.1759051.
    PubMed     Abstract available

    April 2020
  393. BEWERSDORF JP, Shallis RM, Diadamo A, Gowda L, et al
    Isolated trisomy 11 in patients with acute myeloid leukemia - is the prognosis not as grim as previously thought?
    Leuk Lymphoma. 2020 Apr 26:1-4. doi: 10.1080/10428194.2020.1755858.

    Immune dysfunction complexity in chronic lymphocytic leukemia an issue to consider when designing novel therapeutic strategies.
    Leuk Lymphoma. 2020 Apr 26:1-9. doi: 10.1080/10428194.2020.1755857.
    PubMed     Abstract available

  395. THOMPSON ER, Lim KJC, Kuzich JA, McBean M, et al
    Detection of an IGH-BRAF fusion in a patient with BRAF Val600Glu negative hairy cell leukemia.
    Leuk Lymphoma. 2020 Apr 22:1-3. doi: 10.1080/10428194.2020.1753045.

  396. STAHL M, Tallman MS
    Late and very late relapses in acute myeloid leukemia (AML).
    Leuk Lymphoma. 2020 Apr 14:1-2. doi: 10.1080/10428194.2020.1745204.

  397. RAMALINGAM TR, Muthu A, Vaidhyanathan L, Ramakrishnan B, et al
    Immunophenotypic modulation in pediatric B lymphoblastic leukemia and its implications in MRD detection.
    Leuk Lymphoma. 2020 Apr 12:1-7. doi: 10.1080/10428194.2020.1742902.
    PubMed     Abstract available

  398. ZHANG Y, Xiao L
    Identification and validation of a prognostic 8-gene signature for acute myeloid leukemia.
    Leuk Lymphoma. 2020 Apr 8:1-8. doi: 10.1080/10428194.2020.1742898.
    PubMed     Abstract available

  399. GARCIA-MANERO G, Pemmaraju N, Alvarado Y, Naqvi K, et al
    Results of a Phase 1/2a dose-escalation study of FF-10501-01, an IMPDH inhibitor, in patients with acute myeloid leukemia or myelodysplastic syndromes.
    Leuk Lymphoma. 2020 Apr 7:1-11. doi: 10.1080/10428194.2020.1747065.
    PubMed     Abstract available

    March 2020
  400. CAI P, Wu Q, Wang Y, Yang X, et al
    An effective early death scoring system for predicting early death risk in de novo acute promyelocytic leukemia.
    Leuk Lymphoma. 2020 Mar 31:1-7. doi: 10.1080/10428194.2020.1742910.
    PubMed     Abstract available

  401. DUCOURNEAU B, Fenwarth L, Duployez N, Lambert J, et al
    Cytogenetically masked CBFB-MYH11 fusion and concomitant TP53 deletion in a case of acute myeloid leukemia with a complex karyotype.
    Leuk Lymphoma. 2020 Mar 29:1-3. doi: 10.1080/10428194.2020.1742905.

    February 2020
  402. ANSELL SM
    Activation-induced T-cell exhaustion: too much of a good thing?
    Leuk Lymphoma. 2020;61:255-256.

  403. DUPLOYEZ N, Fenwarth L
    Controversies about germline RUNX1 missense variants.
    Leuk Lymphoma. 2020;61:497-499.

    January 2020
  404. RYLAND GL, Fox LC, Wootton V, Thompson ER, et al
    Severe chemotherapy toxicity in a 10-year-old with T-acute lymphoblastic lymphoma harboring biallelic FANCM variants.
    Leuk Lymphoma. 2020 Jan 16:1-3. doi: 10.1080/10428194.2019.1711075.

  405. BROWN AL, Hahn C, Hiwase D, Godley LA, et al
    Correct application of variant classification guidelines in germline RUNX1 mutated disorders to assist clinical diagnosis.
    Leuk Lymphoma. 2020;61:246-247.

  406. PRIETO-CONDE MI, Labrador J, Hermida G, Alonso S, et al
    Reply to Brown et al: 'Correct application of variant classification guidelines in germline RUNX1 mutated disorders to assist clinical diagnosis'.
    Leuk Lymphoma. 2020;61:248-249.

    October 2019
  407. KUMAR P, Uppal M, Xiao W, Dogan A, et al
    Clonally-Related CD5+ CLL/SLL and CD10+ high grade B-cell lymphoma suggests common neoplastic progenitor with branched disease evolution, with therapeutic implications.
    Leuk Lymphoma. 2019 Oct 15:1-5. doi: 10.1080/10428194.2019.1675876.

    September 2019
  408. WANG F, Liu T, Wang L, Gu Z, et al
    Unmanipulated haploidentical peripheral blood stem cell transplantation for patients with Philadelphia-negative acute lymphoblastic leukaemia in first complete remission.
    Leuk Lymphoma. 2019 Sep 13:1-10. doi: 10.1080/10428194.2019.1660965.
    PubMed     Abstract available

    August 2019
  409. BALDUCCI E, Sanekli S, Hugues P, Soubeyrand M, et al
    Co-occurrence of BCR-ABL1 rearrangement and CALR mutation in a single leukemic stem cell: evidence that BCR-ABL1 oncogenic addiction prevails over CALR signaling.
    Leuk Lymphoma. 2019 Aug 29:1-4. doi: 10.1080/10428194.2019.1658101.

    October 2018
  410. LE CLEF Q, Ortega-Sanchez G, Dirnhofer S, Tzankov A, et al
    T-lymphoblastic lymphoma after previous thymoma: how NGS helps establishing the diagnosis and procures new insights.
    Leuk Lymphoma. 2018 Oct 10:1-4. doi: 10.1080/10428194.2018.1520993.

    September 2018
  411. HECKL BC, Carlet M, Vick B, Roolf C, et al
    Frequent and reliable engraftment of certain adult primary acute lymphoblastic leukemias in mice.
    Leuk Lymphoma. 2018 Sep 20:1-4. doi: 10.1080/10428194.2018.1509314.

Thank you for your interest in scientific medicine.

AMEDEO Leukemia is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.